{ "version": "2.2", "instance": { "zk2635990.htm exhibit_2.htm": { "nsprefix": "blrx", "nsuri": "http://biolinerx.com/20260630", "dts": { "schema": { "local": [ "blrx-20260630.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd", "https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd", "https://xbrl.fasb.org/srt/2025/elts/srt-roles-2025.xsd", "https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd", "https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd", "https://xbrl.fasb.org/us-gaap/2025/elts/us-roles-2025.xsd", "https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd", "https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/dimensions-ea/rol_ifrs_ea-dim_2025-03-27.xsd", "https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/dimensions/rol_full_ifrs-dim_2025-03-27.xsd", "https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd", "https://xbrl.sec.gov/country/2025/country-2025.xsd", "https://xbrl.sec.gov/currency/2025/currency-2025.xsd", "https://xbrl.sec.gov/dei/2025/dei-2025.xsd", "https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd", "https://xbrl.sec.gov/ecd/2025/ecd-sub-2025.xsd", "https://xbrl.sec.gov/exch/2025/exch-2025.xsd", "https://xbrl.sec.gov/naics/2025/naics-2025.xsd", "https://xbrl.sec.gov/sic/2025/sic-2025.xsd", "https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd" ] }, "calculationLink": { "local": [ "blrx-20260630_cal.xml" ] }, "definitionLink": { "local": [ "blrx-20260630_def.xml" ], "remote": [ "https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/dimensions-ea/dim_ifrs_ea_2025-03-27_role-995000.xml", "https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/dimensions/dim_full_ifrs_2025-03-27_role-995000.xml" ] }, "labelLink": { "local": [ "blrx-20260630_lab.xml" ] }, "presentationLink": { "local": [ "blrx-20260630_pre.xml" ] }, "inline": { "local": [ "exhibit_2.htm", "zk2635990.htm" ] } }, "keyStandard": 99, "keyCustom": 58, "axisStandard": 7, "axisCustom": 2, "memberStandard": 8, "memberCustom": 15, "hidden": { "total": 4, "http://xbrl.sec.gov/dei/2025": 4 }, "contextCount": 89, "entityCount": 1, "segmentCount": 23, "elementCount": 373, "unitCount": 6, "baseTaxonomies": { "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full": 284, "http://xbrl.sec.gov/dei/2025": 13 }, "report": { "R1": { "role": "http://biolinerx.com/role/DocumentAndEntityInformation", "longName": "0001 - Document - Document and Entity Information", "shortName": "Document and Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "C_20260101to20260630", "name": "dei:EntityRegistrantName", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "strong", "span", "span", "span", "span", "span", "span", "p", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2635990.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_20260101to20260630", "name": "dei:EntityRegistrantName", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "strong", "span", "span", "span", "span", "span", "span", "p", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2635990.htm", "first": true, "unique": true } }, "R2": { "role": "http://biolinerx.com/role/CondensedConsolidatedInterimStatementsOfFinancialPosition", "longName": "0002 - Statement - CONDENSED CONSOLIDATED INTERIM STATEMENTS OF FINANCIAL POSITION (UNAUDITED)", "shortName": "CONDENSED CONSOLIDATED INTERIM STATEMENTS OF FINANCIAL POSITION (UNAUDITED)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "C_20260630", "name": "ifrs-full:CashAndCashEquivalents", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "exhibit_2.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_20260630", "name": "ifrs-full:ShorttermInvestmentsClassifiedAsCashEquivalents", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "exhibit_2.htm", "unique": true } }, "R3": { "role": "http://biolinerx.com/role/CondensedConsolidatedInterimStatementsOfComprehensiveLoss", "longName": "0003 - Statement - CONDENSED CONSOLIDATED INTERIM STATEMENTS OF COMPREHENSIVE INCOME (LOSS) (UNAUDITED)", "shortName": "CONDENSED CONSOLIDATED INTERIM STATEMENTS OF COMPREHENSIVE INCOME (LOSS) (UNAUDITED)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "C_20260401to20260630", "name": "ifrs-full:Revenue", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "exhibit_2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_20260401to20260630", "name": "ifrs-full:Revenue", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "exhibit_2.htm", "first": true, "unique": true } }, "R4": { "role": "http://biolinerx.com/role/CondensedInterimStatementsOfChangesInEquity", "longName": "0004 - Statement - CONDENSED CONSOLIDATED INTERIM STATEMENTS OF CHANGES IN EQUITY (UNAUDITED)", "shortName": "CONDENSED CONSOLIDATED INTERIM STATEMENTS OF CHANGES IN EQUITY (UNAUDITED)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "C_20241231_ifrsfullComponentsOfEquityAxis_ifrsfullIssuedCapitalMember", "name": "ifrs-full:Equity", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "exhibit_2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_20241231_ifrsfullComponentsOfEquityAxis_ifrsfullIssuedCapitalMember", "name": "ifrs-full:Equity", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "exhibit_2.htm", "first": true, "unique": true } }, "R5": { "role": "http://biolinerx.com/role/CondensedConsolidatedInterimCashFlowStatements", "longName": "0005 - Statement - CONDENSED CONSOLIDATED INTERIM STATEMENTS OF CASH FLOWS (UNAUDITED)", "shortName": "CONDENSED CONSOLIDATED INTERIM STATEMENTS OF CASH FLOWS (UNAUDITED)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "C_20260101to20260630", "name": "ifrs-full:ProfitLoss", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "exhibit_2.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_20260101to20260630", "name": "ifrs-full:CashFlowsFromUsedInOperatingActivities", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "td", "tr", "table", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "exhibit_2.htm", "unique": true } }, "R6": { "role": "http://biolinerx.com/role/GeneralInformation", "longName": "0006 - Disclosure - GENERAL INFORMATION", "shortName": "GENERAL INFORMATION", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "6", "firstAnchor": { "contextRef": "C_20260101to20260630", "name": "ifrs-full:DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "exhibit_2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_20260101to20260630", "name": "ifrs-full:DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "exhibit_2.htm", "first": true, "unique": true } }, "R7": { "role": "http://biolinerx.com/role/BasisOfPreparation", "longName": "0007 - Disclosure - BASIS OF PREPARATION", "shortName": "BASIS OF PREPARATION", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "7", "firstAnchor": { "contextRef": "C_20260101to20260630", "name": "ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "exhibit_2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_20260101to20260630", "name": "ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "exhibit_2.htm", "first": true, "unique": true } }, "R8": { "role": "http://biolinerx.com/role/SignificantAccountingPolicies", "longName": "0008 - Disclosure - MATERIAL ACCOUNTING POLICIES", "shortName": "MATERIAL ACCOUNTING POLICIES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "8", "firstAnchor": { "contextRef": "C_20260101to20260630", "name": "ifrs-full:DisclosureOfMaterialAccountingPolicyInformationExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "exhibit_2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_20260101to20260630", "name": "ifrs-full:DisclosureOfMaterialAccountingPolicyInformationExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "exhibit_2.htm", "first": true, "unique": true } }, "R9": { "role": "http://biolinerx.com/role/At-the-marketAtmSalesAgreementWithBtig", "longName": "0009 - Disclosure - AT-THE-MARKET (\"ATM\") SALES AGREEMENT WITH HCW", "shortName": "AT-THE-MARKET (\"ATM\") SALES AGREEMENT WITH HCW", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "C_20260101to20260630", "name": "blrx:DisclosureOfMarketAtmSalesAgreementWithBtigExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "exhibit_2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_20260101to20260630", "name": "blrx:DisclosureOfMarketAtmSalesAgreementWithBtigExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "exhibit_2.htm", "first": true, "unique": true } }, "R10": { "role": "http://biolinerx.com/role/EQUITYFINANCING", "longName": "0010 - Disclosure - FINANCINGS", "shortName": "FINANCINGS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "C_20260101to20260630", "name": "blrx:DisclosureOfEquityFinancingExplanatoryTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "exhibit_2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_20260101to20260630", "name": "blrx:DisclosureOfEquityFinancingExplanatoryTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "exhibit_2.htm", "first": true, "unique": true } }, "R11": { "role": "http://biolinerx.com/role/FAIRVALUEMEASUREMENTOFWARRANTSUSINGSIGNIFICANTUNOBSERVABLEINPUTSLEVEL3", "longName": "0011 - Disclosure - FAIR VALUE MEASUREMENT OF WARRANTS USING SIGNIFICANT UNOBSERVABLE INPUTS (LEVEL 3)", "shortName": "FAIR VALUE MEASUREMENT OF WARRANTS USING SIGNIFICANT UNOBSERVABLE INPUTS (LEVEL 3)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "C_20260101to20260630", "name": "ifrs-full:DisclosureOfFairValueMeasurementExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "exhibit_2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_20260101to20260630", "name": "ifrs-full:DisclosureOfFairValueMeasurementExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "exhibit_2.htm", "first": true, "unique": true } }, "R12": { "role": "http://biolinerx.com/role/ShareholdersEquity", "longName": "0012 - Disclosure - SHAREHOLDERS' EQUITY", "shortName": "SHAREHOLDERS' EQUITY", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "C_20260101to20260630", "name": "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "exhibit_2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_20260101to20260630", "name": "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "exhibit_2.htm", "first": true, "unique": true } }, "R13": { "role": "http://biolinerx.com/role/AGREEMENTWITHHEMISPHERIANFORDEVELOPMENTOFGLIX1", "longName": "0013 - Disclosure - AGREEMENT WITH HEMISPHERIAN FOR DEVELOPMENT OF GLIX1", "shortName": "AGREEMENT WITH HEMISPHERIAN FOR DEVELOPMENT OF GLIX1", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "C_20260101to20260630", "name": "blrx:AgreementWithHemispherianForDevelopmentOfGlix1Explanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "exhibit_2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_20260101to20260630", "name": "blrx:AgreementWithHemispherianForDevelopmentOfGlix1Explanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "exhibit_2.htm", "first": true, "unique": true } }, "R14": { "role": "http://biolinerx.com/role/SUBSEQUENTEVENTS", "longName": "0014 - Disclosure - SUBSEQUENT EVENT", "shortName": "SUBSEQUENT EVENT", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "C_20260101to20260630", "name": "ifrs-full:DisclosureOfNonadjustingEventsAfterReportingPeriodExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "exhibit_2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_20260101to20260630", "name": "ifrs-full:DisclosureOfNonadjustingEventsAfterReportingPeriodExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "exhibit_2.htm", "first": true, "unique": true } }, "R15": { "role": "http://biolinerx.com/role/MATERIALACCOUNTINGPOLICIESPolicies", "longName": "9960701 - Disclosure - MATERIAL ACCOUNTING POLICIES (Policies)", "shortName": "MATERIAL ACCOUNTING POLICIES (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "15", "firstAnchor": { "contextRef": "C_20260101to20260630", "name": "blrx:DescriptionOfAccountingPolicyForGeneralDisclosuresExplanatoryPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "ifrs-full:DisclosureOfMaterialAccountingPolicyInformationExplanatory", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "exhibit_2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_20260101to20260630", "name": "blrx:DescriptionOfAccountingPolicyForGeneralDisclosuresExplanatoryPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "ifrs-full:DisclosureOfMaterialAccountingPolicyInformationExplanatory", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "exhibit_2.htm", "first": true, "unique": true } }, "R16": { "role": "http://biolinerx.com/role/FAIRVALUEMEASUREMENTOFWARRANTSUSINGSIGNIFICANTUNOBSERVABLEINPUTSLEVEL3Tables", "longName": "9960702 - Disclosure - FAIR VALUE MEASUREMENT OF WARRANTS USING SIGNIFICANT UNOBSERVABLE INPUTS (LEVEL 3) (Tables)", "shortName": "FAIR VALUE MEASUREMENT OF WARRANTS USING SIGNIFICANT UNOBSERVABLE INPUTS (LEVEL 3) (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "16", "firstAnchor": { "contextRef": "C_20260101to20260630", "name": "ifrs-full:DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfFairValueMeasurementExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "exhibit_2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_20260101to20260630", "name": "ifrs-full:DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfFairValueMeasurementExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "exhibit_2.htm", "first": true, "unique": true } }, "R17": { "role": "http://biolinerx.com/role/ShareholdersEquityTables", "longName": "9960703 - Disclosure - SHAREHOLDERS' EQUITY (Tables)", "shortName": "SHAREHOLDERS' EQUITY (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "17", "firstAnchor": { "contextRef": "C_20260101to20260630", "name": "ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "exhibit_2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_20260101to20260630", "name": "ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "exhibit_2.htm", "first": true, "unique": true } }, "R18": { "role": "http://biolinerx.com/role/GENERALINFORMATIONNarrativeDetails", "longName": "9960704 - Disclosure - GENERAL INFORMATION (Narrative) (Details)", "shortName": "GENERAL INFORMATION (Narrative) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "18", "firstAnchor": { "contextRef": "C_20260101to20260630", "name": "blrx:NumberOfAmericanDepositaryOrdinarySharesTraded", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "div", "ifrs-full:DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "exhibit_2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_20260101to20260630", "name": "blrx:NumberOfAmericanDepositaryOrdinarySharesTraded", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "div", "ifrs-full:DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "exhibit_2.htm", "first": true, "unique": true } }, "R19": { "role": "http://biolinerx.com/role/At-the-marketAtmSalesAgreementWithBtigDetails", "longName": "9960705 - Disclosure - AT-THE-MARKET (\"ATM\") SALES AGREEMENT WITH HCW (Narrative) (Details)", "shortName": "AT-THE-MARKET (\"ATM\") SALES AGREEMENT WITH HCW (Narrative) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "19", "firstAnchor": { "contextRef": "C_20260630_ifrsfullCategoriesOfRelatedPartiesAxis_blrxHcwMember", "name": "blrx:AggregateOfferingPrice", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "div", "blrx:DisclosureOfMarketAtmSalesAgreementWithBtigExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "exhibit_2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_20260630_ifrsfullCategoriesOfRelatedPartiesAxis_blrxHcwMember", "name": "blrx:AggregateOfferingPrice", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "div", "blrx:DisclosureOfMarketAtmSalesAgreementWithBtigExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "exhibit_2.htm", "first": true, "unique": true } }, "R20": { "role": "http://biolinerx.com/role/EQUITYFINANCINGNarrativeDetails", "longName": "9960706 - Disclosure - FINANCINGS (Narrative) (Details)", "shortName": "FINANCINGS (Narrative) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "20", "firstAnchor": { "contextRef": "C_20220901to20220930_ifrsfullClassesOfFinancialInstrumentsAxis_blrxAmericanDepositarySharesMember_ifrsfullTypesOfInvestmentPropertyAxis_blrxSeptember2022OfferingMember", "name": "blrx:SharesIssuedRegisteredDirectOfferings", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "div", "blrx:DisclosureOfEquityFinancingExplanatoryTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "exhibit_2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_20220901to20220930_ifrsfullClassesOfFinancialInstrumentsAxis_blrxAmericanDepositarySharesMember_ifrsfullTypesOfInvestmentPropertyAxis_blrxSeptember2022OfferingMember", "name": "blrx:SharesIssuedRegisteredDirectOfferings", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "div", "blrx:DisclosureOfEquityFinancingExplanatoryTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "exhibit_2.htm", "first": true, "unique": true } }, "R21": { "role": "http://biolinerx.com/role/FAIRVALUEMEASUREMENTOFWARRANTSUSINGSIGNIFICANTUNOBSERVABLEINPUTSLEVEL3Details", "longName": "9960707 - Disclosure - FAIR VALUE MEASUREMENT OF WARRANTS USING SIGNIFICANT UNOBSERVABLE INPUTS (LEVEL 3) (Details)", "shortName": "FAIR VALUE MEASUREMENT OF WARRANTS USING SIGNIFICANT UNOBSERVABLE INPUTS (LEVEL 3) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "21", "firstAnchor": { "contextRef": "C_20251231", "name": "blrx:Warrants", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "exhibit_2.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_20251231_ifrsfullLevelsOfFairValueHierarchyAxis_ifrsfullLevel3OfFairValueHierarchyMember_ifrsfullMeasurementAxis_ifrsfullAtFairValueMember", "name": "blrx:Warrants", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "div", "ifrs-full:DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesExplanatory", "ifrs-full:DisclosureOfFairValueMeasurementExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "exhibit_2.htm", "unique": true } }, "R22": { "role": "http://biolinerx.com/role/ShareholdersEquityScheduleOfShareCapitalDetails", "longName": "9960708 - Disclosure - SHAREHOLDERS' EQUITY (Schedule of Share Capital) (Details)", "shortName": "SHAREHOLDERS' EQUITY (Schedule of Share Capital) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "22", "firstAnchor": { "contextRef": "C_20260630", "name": "ifrs-full:NumberOfSharesAuthorised", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "span", "td", "tr", "table", "div", "div", "ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory", "div", "div", "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "exhibit_2.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_20260630", "name": "blrx:AuthorizedShareCapitalValue", "unitRef": "ILS", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "span", "td", "tr", "table", "div", "div", "ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory", "div", "div", "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "exhibit_2.htm", "unique": true } }, "R23": { "role": "http://biolinerx.com/role/AGREEMENTWITHHEMISPHERIANFORDEVELOPMENTOFGLIX1NarrativeDetails", "longName": "9960709 - Disclosure - AGREEMENT WITH HEMISPHERIAN FOR DEVELOPMENT OF GLIX1 (Narrative) (Details)", "shortName": "AGREEMENT WITH HEMISPHERIAN FOR DEVELOPMENT OF GLIX1 (Narrative) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "23", "firstAnchor": { "contextRef": "C_20250901to20250930_blrxAgreementTypeAxis_blrxAssetTransferAgreementMember_blrxCollaborationTransactionAxis_blrxHemispherianAsMember_ifrsfullCategoriesOfRelatedPartiesAxis_blrxTetragonMember", "name": "blrx:PercentageOfIssuedShareCapitalReceived", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "span", "span", "p", "div", "div", "blrx:AgreementWithHemispherianForDevelopmentOfGlix1Explanatory", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "exhibit_2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_20250901to20250930_blrxAgreementTypeAxis_blrxAssetTransferAgreementMember_blrxCollaborationTransactionAxis_blrxHemispherianAsMember_ifrsfullCategoriesOfRelatedPartiesAxis_blrxTetragonMember", "name": "blrx:PercentageOfIssuedShareCapitalReceived", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "span", "span", "p", "div", "div", "blrx:AgreementWithHemispherianForDevelopmentOfGlix1Explanatory", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "exhibit_2.htm", "first": true, "unique": true } }, "R24": { "role": "http://biolinerx.com/role/SUBSEQUENTEVENTNarrativeDetails", "longName": "9960710 - Disclosure - SUBSEQUENT EVENT (Narrative) (Details)", "shortName": "SUBSEQUENT EVENT (Narrative) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "24", "firstAnchor": { "contextRef": "C_20260801to20260827_ifrsfullClassesOfFinancialInstrumentsAxis_blrxPreFundedWarrantsMember_ifrsfullNonadjustingEventsAfterReportingPeriodAxis_blrxDefinitiveAgreementInstitutionalInvestorMember", "name": "blrx:NumberOfAmericanDepositarySharesIssuedToInvestors", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "span", "p", "div", "ifrs-full:DisclosureOfNonadjustingEventsAfterReportingPeriodExplanatory", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "exhibit_2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_20260801to20260827_ifrsfullClassesOfFinancialInstrumentsAxis_blrxPreFundedWarrantsMember_ifrsfullNonadjustingEventsAfterReportingPeriodAxis_blrxDefinitiveAgreementInstitutionalInvestorMember", "name": "blrx:NumberOfAmericanDepositarySharesIssuedToInvestors", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "span", "p", "div", "ifrs-full:DisclosureOfNonadjustingEventsAfterReportingPeriodExplanatory", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "exhibit_2.htm", "first": true, "unique": true } } }, "tag": { "ifrs-full_AccumulatedOtherComprehensiveIncome": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AccumulatedOtherComprehensiveIncome", "crdr": "credit", "calculation": { "http://biolinerx.com/role/CondensedConsolidatedInterimStatementsOfFinancialPosition": { "parentTag": "ifrs-full_EquityAttributableToOwnersOfParent", "weight": 1.0, "order": 40.0 } }, "presentation": [ "http://biolinerx.com/role/CondensedConsolidatedInterimStatementsOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Other comprehensive loss" } } }, "auth_ref": [ "r251" ] }, "ifrs-full_AcquisitionsThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AcquisitionsThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill", "crdr": "debit", "presentation": [ "http://biolinerx.com/role/AGREEMENTWITHHEMISPHERIANFORDEVELOPMENTOFGLIX1NarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Acquisitions through business combinations, intangible assets other than goodwill", "terseLabel": "Intangible asset amount" } }, "en": { "role": { "documentation": "The increase in intangible assets other than goodwill resulting from acquisitions through business combinations. [Refer: Total for all business combinations [member]; Intangible assets other than goodwill]" } } }, "auth_ref": [ "r13", "r89" ] }, "ecd_Additional402vDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "Additional402vDisclosureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Additional 402(v) Disclosure [Text Block]", "terseLabel": "Additional 402(v) Disclosure" } } }, "auth_ref": [ "r191" ] }, "ecd_AdjToCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AdjToCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Adjustment to Compensation Amount", "terseLabel": "Adjustment to Compensation, Amount" } } }, "auth_ref": [ "r204" ] }, "ecd_AdjToCompAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AdjToCompAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Adjustment to Compensation [Axis]", "terseLabel": "Adjustment to Compensation:" } } }, "auth_ref": [ "r204" ] }, "ecd_AdjToNonPeoNeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AdjToNonPeoNeoCompFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]", "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote" } } }, "auth_ref": [ "r204" ] }, "ecd_AdjToPeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AdjToPeoCompFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Adjustment To PEO Compensation, Footnote [Text Block]", "terseLabel": "Adjustment To PEO Compensation, Footnote" } } }, "auth_ref": [ "r204" ] }, "ifrs-full_AdjustedWeightedAverageShares": { "xbrltype": "sharesItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AdjustedWeightedAverageShares", "presentation": [ "http://biolinerx.com/role/CondensedConsolidatedInterimStatementsOfComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Weighted average number of ordinary shares used in calculating diluted earnings per share", "totalLabel": "WEIGHTED AVERAGE NUMBER OF SHARES USED IN CALCULATION OF EARNINGS (LOSS) PER SHARE - DILUTED", "terseLabel": "LOSS PER ORDINARY SHARE \u2013 DILUTED", "verboseLabel": "WEIGHTED AVERAGE NUMBER OF SHARES USED IN CALCULATION OF DILUTED EARNINGS (LOSS) PER ORDINARY SHARE" } }, "en": { "role": { "documentation": "The weighted average number of ordinary shares outstanding plus the weighted average number of ordinary shares that would be issued on the conversion of all the dilutive potential ordinary shares into ordinary shares. [Refer: Ordinary shares [member]; Weighted average [member]]" } } }, "auth_ref": [ "r10" ] }, "ifrs-full_AdjustmentsForDecreaseIncreaseInInventories": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AdjustmentsForDecreaseIncreaseInInventories", "crdr": "debit", "calculation": { "http://biolinerx.com/role/CondensedConsolidatedInterimCashFlowStatements": { "parentTag": "blrx_TotalChangeInOperatingAssetAndLiability", "weight": 1.0, "order": 20.0 } }, "presentation": [ "http://biolinerx.com/role/CondensedConsolidatedInterimCashFlowStatements" ], "lang": { "en-us": { "role": { "label": "Adjustments for decrease (increase) in inventories", "verboseLabel": "Decrease (increase) in inventory" } } }, "auth_ref": [ "r243" ] }, "blrx_AdjustmentsForDecreaseIncreaseInPrepaidExpensesAndOtherOperatingReceivables": { "xbrltype": "monetaryItemType", "nsuri": "http://biolinerx.com/20260630", "localname": "AdjustmentsForDecreaseIncreaseInPrepaidExpensesAndOtherOperatingReceivables", "crdr": "credit", "calculation": { "http://biolinerx.com/role/CondensedConsolidatedInterimCashFlowStatements": { "parentTag": "blrx_TotalChangeInOperatingAssetAndLiability", "weight": -1.0, "order": 10.0 } }, "presentation": [ "http://biolinerx.com/role/CondensedConsolidatedInterimCashFlowStatements" ], "lang": { "en-us": { "role": { "documentation": "Adjustments for decrease (increase) in prepaid expense other operating receivables to reconcile profit (loss) to net cash flow from (used in) operating activities.", "negatedLabel": "Decrease (increase) in prepaid expenses and other receivables", "label": "Adjustments For Decrease Increase In Prepaid Expenses And Other Operating Receivables" } } }, "auth_ref": [] }, "ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables", "crdr": "debit", "calculation": { "http://biolinerx.com/role/CondensedConsolidatedInterimCashFlowStatements": { "parentTag": "blrx_TotalChangeInOperatingAssetAndLiability", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://biolinerx.com/role/CondensedConsolidatedInterimCashFlowStatements" ], "lang": { "en-us": { "role": { "label": "Adjustments for decrease (increase) in trade and other receivables", "verboseLabel": "Decrease in trade receivables" } }, "en": { "role": { "documentation": "Adjustments for decrease (increase) in trade and other receivables to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Trade and other receivables; Profit (loss)]" } } }, "auth_ref": [ "r245" ] }, "ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AdjustmentsForDepreciationAndAmortisationExpense", "crdr": "debit", "calculation": { "http://biolinerx.com/role/CondensedConsolidatedInterimCashFlowStatements": { "parentTag": "blrx_TotalIncomeAndExpenseNotInvolvingCashFlows", "weight": 1.0, "order": 60.0 } }, "presentation": [ "http://biolinerx.com/role/CondensedConsolidatedInterimCashFlowStatements" ], "lang": { "en-us": { "role": { "label": "Depreciation and amortization" } } }, "auth_ref": [ "r244" ] }, "ifrs-full_AdjustmentsForFairValueGainsLosses": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AdjustmentsForFairValueGainsLosses", "crdr": "debit", "calculation": { "http://biolinerx.com/role/CondensedConsolidatedInterimCashFlowStatements": { "parentTag": "blrx_TotalIncomeAndExpenseNotInvolvingCashFlows", "weight": 1.0, "order": 40.0 } }, "presentation": [ "http://biolinerx.com/role/CondensedConsolidatedInterimCashFlowStatements" ], "lang": { "en-us": { "role": { "label": "Fair value adjustments of warrants" } } }, "auth_ref": [ "r244" ] }, "ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AdjustmentsForIncreaseDecreaseInTradeAccountPayable", "crdr": "debit", "calculation": { "http://biolinerx.com/role/CondensedConsolidatedInterimCashFlowStatements": { "parentTag": "blrx_TotalChangeInOperatingAssetAndLiability", "weight": 1.0, "order": 30.0 } }, "presentation": [ "http://biolinerx.com/role/CondensedConsolidatedInterimCashFlowStatements" ], "lang": { "en-us": { "role": { "label": "Adjustments for increase (decrease) in trade accounts payable", "terseLabel": "Increase (decrease) in accounts payable and accruals" } } }, "auth_ref": [ "r243" ] }, "ifrs-full_AdjustmentsForReconcileProfitLoss": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AdjustmentsForReconcileProfitLoss", "crdr": "debit", "calculation": { "http://biolinerx.com/role/CondensedConsolidatedInterimCashFlowStatements": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://biolinerx.com/role/CondensedConsolidatedInterimCashFlowStatements" ], "lang": { "en-us": { "role": { "label": "Adjustments to reconcile profit (loss)", "terseLabel": "Adjustments required to reflect net cash used in operating activities (see appendix below)", "totalLabel": "Total Adjustments required to reflect net cash used in operating acivities" } } }, "auth_ref": [ "r21" ] }, "ifrs-full_AdjustmentsForSharebasedPayments": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AdjustmentsForSharebasedPayments", "crdr": "debit", "calculation": { "http://biolinerx.com/role/CondensedConsolidatedInterimCashFlowStatements": { "parentTag": "blrx_TotalIncomeAndExpenseNotInvolvingCashFlows", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://biolinerx.com/role/CondensedConsolidatedInterimCashFlowStatements" ], "lang": { "en-us": { "role": { "label": "Adjustments for share-based payments", "verboseLabel": "Share-based compensation" } } }, "auth_ref": [ "r244" ] }, "ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AdjustmentsForUnrealisedForeignExchangeLossesGains", "crdr": "debit", "calculation": { "http://biolinerx.com/role/CondensedConsolidatedInterimCashFlowStatements": { "parentTag": "blrx_TotalIncomeAndExpenseNotInvolvingCashFlows", "weight": 1.0, "order": 30.0 } }, "presentation": [ "http://biolinerx.com/role/CondensedConsolidatedInterimCashFlowStatements" ], "lang": { "en-us": { "role": { "label": "Exchange differences on cash and cash equivalents" } } }, "auth_ref": [ "r146", "r244" ] }, "blrx_AdjustmentsRequiredToReflectNetCashUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://biolinerx.com/20260630", "localname": "AdjustmentsRequiredToReflectNetCashUsedInOperatingActivitiesAbstract", "presentation": [ "http://biolinerx.com/role/CondensedConsolidatedInterimCashFlowStatements" ], "lang": { "en-us": { "role": { "label": "Adjustments Required To Reflect Net Cash Used In Operating Activities [Abstract]", "verboseLabel": "Adjustments required to reflect net cash used in operating activities:" } } }, "auth_ref": [] }, "blrx_AggregateOfferingPrice": { "xbrltype": "monetaryItemType", "nsuri": "http://biolinerx.com/20260630", "localname": "AggregateOfferingPrice", "crdr": "credit", "presentation": [ "http://biolinerx.com/role/At-the-marketAtmSalesAgreementWithBtigDetails", "http://biolinerx.com/role/EQUITYFINANCINGNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Aggregate offering price.", "label": "Aggregate offering price", "verboseLabel": "Aggregate offering price" } } }, "auth_ref": [] }, "ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AggtChngPnsnValInSummryCompstnTblForAplblYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]", "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table" } } }, "auth_ref": [ "r237" ] }, "ecd_AggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AggtErrCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Aggregate Erroneous Compensation Amount", "terseLabel": "Aggregate Erroneous Compensation Amount" } } }, "auth_ref": [ "r164", "r174", "r184", "r215" ] }, "ecd_AggtErrCompNotYetDeterminedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AggtErrCompNotYetDeterminedTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]", "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined" } } }, "auth_ref": [ "r167", "r177", "r187", "r218" ] }, "ecd_AggtPnsnAdjsSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AggtPnsnAdjsSvcCstMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Aggregate Pension Adjustments Service Cost [Member]", "terseLabel": "Aggregate Pension Adjustments Service Cost" } } }, "auth_ref": [ "r238" ] }, "blrx_AgreementTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://biolinerx.com/20260630", "localname": "AgreementTypeAxis", "presentation": [ "http://biolinerx.com/role/AGREEMENTWITHHEMISPHERIANFORDEVELOPMENTOFGLIX1NarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents about agreement type .", "label": "Agreement Type [Axis]" } } }, "auth_ref": [] }, "blrx_AgreementTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://biolinerx.com/20260630", "localname": "AgreementTypeDomain", "presentation": [ "http://biolinerx.com/role/AGREEMENTWITHHEMISPHERIANFORDEVELOPMENTOFGLIX1NarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Agreement Type [Domain]" } } }, "auth_ref": [] }, "blrx_AgreementWithCompaniesForDevelopmentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://biolinerx.com/20260630", "localname": "AgreementWithCompaniesForDevelopmentAbstract", "lang": { "en-us": { "role": { "label": "Agreement With Companies For Development [Abstract]" } } }, "auth_ref": [] }, "blrx_AgreementWithHemispherianForDevelopmentOfGlix1Explanatory": { "xbrltype": "textBlockItemType", "nsuri": "http://biolinerx.com/20260630", "localname": "AgreementWithHemispherianForDevelopmentOfGlix1Explanatory", "presentation": [ "http://biolinerx.com/role/AGREEMENTWITHHEMISPHERIANFORDEVELOPMENTOFGLIX1" ], "lang": { "en-us": { "role": { "documentation": "The disclosure of agreement with hemispherian for development of Glix1.", "label": "Agreement With Hemispherian For Development Of Glix1 Explanatory", "terseLabel": "AGREEMENT WITH HEMISPHERIAN FOR DEVELOPMENT OF GLIX1" } } }, "auth_ref": [] }, "ecd_AllAdjToCompMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AllAdjToCompMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "All Adjustments to Compensation [Member]", "terseLabel": "All Adjustments to Compensation" } } }, "auth_ref": [ "r204" ] }, "currency_AllCurrenciesDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/currency/2025", "localname": "AllCurrenciesDomain", "presentation": [ "http://biolinerx.com/role/ShareholdersEquityScheduleOfShareCapitalDetails" ], "auth_ref": [] }, "ecd_AllExecutiveCategoriesMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AllExecutiveCategoriesMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "All Executive Categories [Member]", "terseLabel": "All Executive Categories" } } }, "auth_ref": [ "r211" ] }, "ecd_AllIndividualsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AllIndividualsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "All Individuals [Member]", "terseLabel": "All Individuals" } } }, "auth_ref": [ "r168", "r178", "r188", "r211", "r219", "r223", "r231" ] }, "ecd_AllTradingArrangementsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AllTradingArrangementsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "All Trading Arrangements [Member]", "terseLabel": "All Trading Arrangements" } } }, "auth_ref": [ "r229" ] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "AmendmentFlag", "presentation": [ "http://biolinerx.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "blrx_AmericanDepositarySharesMember": { "xbrltype": "domainItemType", "nsuri": "http://biolinerx.com/20260630", "localname": "AmericanDepositarySharesMember", "presentation": [ "http://biolinerx.com/role/EQUITYFINANCINGNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "ADSs [Member]", "label": "American Depositary Shares Member", "terseLabel": "ADSs [Member]" } } }, "auth_ref": [] }, "blrx_AmericanDepositarySharesPurchasePricePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://biolinerx.com/20260630", "localname": "AmericanDepositarySharesPurchasePricePerShare", "presentation": [ "http://biolinerx.com/role/SUBSEQUENTEVENTNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "American Depositary Shares Purchase Price Per Share", "documentation": "It represents American depositary shares purchase price per share.", "verboseLabel": "ADS purchase price per share" } } }, "auth_ref": [] }, "blrx_AmericanDepositarySharesSold": { "xbrltype": "sharesItemType", "nsuri": "http://biolinerx.com/20260630", "localname": "AmericanDepositarySharesSold", "presentation": [ "http://biolinerx.com/role/At-the-marketAtmSalesAgreementWithBtigDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the number of american depositary shares sold", "label": "American Depositary Shares Sold", "verboseLabel": "Number of American depositary shares sold" } } }, "auth_ref": [] }, "blrx_AmountAllocatedToWarrant": { "xbrltype": "monetaryItemType", "nsuri": "http://biolinerx.com/20260630", "localname": "AmountAllocatedToWarrant", "crdr": "credit", "presentation": [ "http://biolinerx.com/role/EQUITYFINANCINGNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount allocated to warrant.", "label": "Amount allocated to warrant", "verboseLabel": "Amount allocated to warrant" } } }, "auth_ref": [] }, "blrx_AmountOfFairValueAdjustmentOfWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://biolinerx.com/20260630", "localname": "AmountOfFairValueAdjustmentOfWarrants", "crdr": "credit", "presentation": [ "http://biolinerx.com/role/EQUITYFINANCINGNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Amount Of Fair Value Adjustment Of Warrants", "documentation": "Represent the amount of fair value adjustment of warrants.", "terseLabel": "Amount of fair value adjustment of warrants" } } }, "auth_ref": [] }, "blrx_April2024OfferingMember": { "xbrltype": "domainItemType", "nsuri": "http://biolinerx.com/20260630", "localname": "April2024OfferingMember", "presentation": [ "http://biolinerx.com/role/EQUITYFINANCINGNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "April 2024 Offering [Member]", "documentation": "April 2024 Offering [Member]" } } }, "auth_ref": [] }, "blrx_AssetTransferAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://biolinerx.com/20260630", "localname": "AssetTransferAgreementMember", "presentation": [ "http://biolinerx.com/role/AGREEMENTWITHHEMISPHERIANFORDEVELOPMENTOFGLIX1NarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Asset Transfer Agreement [Member]" } } }, "auth_ref": [] }, "ifrs-full_Assets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "Assets", "crdr": "debit", "calculation": { "http://biolinerx.com/role/CondensedConsolidatedInterimStatementsOfFinancialPosition": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://biolinerx.com/role/CondensedConsolidatedInterimStatementsOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Assets [Default Label]", "totalLabel": "Total assets" } }, "en": { "role": { "documentation": "The amount of a present economic resource controlled by the entity as a result of past events. Economic resource is a right that has the potential to produce economic benefits." } } }, "auth_ref": [ "r41", "r42", "r44", "r64", "r67", "r102", "r103", "r126" ] }, "ifrs-full_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AssetsAbstract", "presentation": [ "http://biolinerx.com/role/CondensedConsolidatedInterimStatementsOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Assets" } } }, "auth_ref": [] }, "ifrs-full_AtFairValueMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AtFairValueMember", "presentation": [ "http://biolinerx.com/role/FAIRVALUEMEASUREMENTOFWARRANTSUSINGSIGNIFICANTUNOBSERVABLEINPUTSLEVEL3Details" ], "lang": { "en-us": { "role": { "terseLabel": "Fair value [Member]", "label": "At fair value [member]" } }, "en": { "role": { "documentation": "This member stands for measurement based on fair value. Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date." } } }, "auth_ref": [ "r16", "r19", "r33", "r41", "r94", "r101", "r102" ] }, "blrx_AuthorizedShareCapitalValue": { "xbrltype": "monetaryItemType", "nsuri": "http://biolinerx.com/20260630", "localname": "AuthorizedShareCapitalValue", "crdr": "credit", "presentation": [ "http://biolinerx.com/role/ShareholdersEquityScheduleOfShareCapitalDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of authorized share capital.", "label": "Authorized Share Capital Value", "verboseLabel": "Authorized share capital" } } }, "auth_ref": [] }, "ecd_AwardExrcPrice": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AwardExrcPrice", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Exercise Price", "terseLabel": "Exercise Price" } } }, "auth_ref": [ "r226" ] }, "ecd_AwardGrantDateFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AwardGrantDateFairValue", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Grant Date Fair Value", "terseLabel": "Fair Value as of Grant Date" } } }, "auth_ref": [ "r227" ] }, "ecd_AwardTmgDiscLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AwardTmgDiscLineItems", "lang": { "en-us": { "role": { "label": "Award Timing Disclosures [Line Items]", "terseLabel": "Award Timing Disclosures" } } }, "auth_ref": [ "r222" ] }, "ecd_AwardTmgHowMnpiCnsdrdTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AwardTmgHowMnpiCnsdrdTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing, How MNPI Considered [Text Block]", "terseLabel": "Award Timing, How MNPI Considered" } } }, "auth_ref": [ "r222" ] }, "ecd_AwardTmgMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AwardTmgMethodTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing Method [Text Block]", "terseLabel": "Award Timing Method" } } }, "auth_ref": [ "r222" ] }, "ecd_AwardTmgMnpiCnsdrdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AwardTmgMnpiCnsdrdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing MNPI Considered [Flag]", "terseLabel": "Award Timing MNPI Considered" } } }, "auth_ref": [ "r222" ] }, "ecd_AwardTmgMnpiDiscTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AwardTmgMnpiDiscTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing MNPI Disclosure [Text Block]", "terseLabel": "Award Timing MNPI Disclosure" } } }, "auth_ref": [ "r222" ] }, "ecd_AwardTmgPredtrmndFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AwardTmgPredtrmndFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing Predetermined [Flag]", "terseLabel": "Award Timing Predetermined" } } }, "auth_ref": [ "r222" ] }, "us-gaap_AwardTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "AwardTypeAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Type [Axis]", "terseLabel": "Award Type" } } }, "auth_ref": [] }, "ecd_AwardUndrlygSecuritiesAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AwardUndrlygSecuritiesAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Underlying Securities Amount", "terseLabel": "Underlying Securities" } } }, "auth_ref": [ "r225" ] }, "ecd_AwardsCloseToMnpiDiscIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AwardsCloseToMnpiDiscIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures, Individual Name", "terseLabel": "Name" } } }, "auth_ref": [ "r224" ] }, "ecd_AwardsCloseToMnpiDiscTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AwardsCloseToMnpiDiscTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures [Table]", "terseLabel": "Awards Close in Time to MNPI Disclosures" } } }, "auth_ref": [ "r223" ] }, "ecd_AwardsCloseToMnpiDiscTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AwardsCloseToMnpiDiscTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]", "terseLabel": "Awards Close in Time to MNPI Disclosures, Table" } } }, "auth_ref": [ "r223" ] }, "ifrs-full_BasicEarningsLossPerShare": { "xbrltype": "perShareItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "BasicEarningsLossPerShare", "presentation": [ "http://biolinerx.com/role/CondensedConsolidatedInterimStatementsOfComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Basic earnings (loss) per share", "terseLabel": "Basic earnings (loss) per share", "verboseLabel": "EARNINGS (LOSS) PER ORDINARY SHARE \u2013 BASIC ATTRIBUTABLE TO OWNERS OF THE COMPANY" } }, "en": { "role": { "documentation": "The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator) divided by the weighted average number of ordinary shares outstanding during the period (the denominator)." } } }, "auth_ref": [ "r8", "r9" ] }, "blrx_BeneficiallyOwnInExcess": { "xbrltype": "percentItemType", "nsuri": "http://biolinerx.com/20260630", "localname": "BeneficiallyOwnInExcess", "presentation": [ "http://biolinerx.com/role/EQUITYFINANCINGNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Beneficially Own In Excess", "documentation": "Represent information about the beneficially own in excess.", "terseLabel": "Beneficially own in excess" } } }, "auth_ref": [] }, "ifrs-full_CapitalReserve": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CapitalReserve", "crdr": "credit", "calculation": { "http://biolinerx.com/role/CondensedConsolidatedInterimStatementsOfFinancialPosition": { "parentTag": "ifrs-full_EquityAttributableToOwnersOfParent", "weight": 1.0, "order": 30.0 } }, "presentation": [ "http://biolinerx.com/role/CondensedConsolidatedInterimStatementsOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Capital reserve" } }, "en": { "role": { "documentation": "A component of equity representing the capital reserves." } } }, "auth_ref": [ "r251" ] }, "ifrs-full_CapitalReserveMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CapitalReserveMember", "presentation": [ "http://biolinerx.com/role/CondensedInterimStatementsOfChangesInEquity" ], "lang": { "en-us": { "role": { "label": "Capital reserve [Member]" } }, "en": { "role": { "documentation": "This member stands for a component of equity representing capital reserves." } } }, "auth_ref": [ "r249" ] }, "ifrs-full_CashAndCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CashAndCashEquivalents", "crdr": "debit", "calculation": { "http://biolinerx.com/role/CondensedConsolidatedInterimStatementsOfFinancialPosition": { "parentTag": "ifrs-full_CurrentAssets", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://biolinerx.com/role/CondensedConsolidatedInterimCashFlowStatements", "http://biolinerx.com/role/CondensedConsolidatedInterimStatementsOfFinancialPosition" ], "lang": { "en-us": { "role": { "periodEndLabel": "CASH AND CASH EQUIVALENTS - END OF PERIOD", "periodStartLabel": "CASH AND CASH EQUIVALENTS - BEGINNING OF PERIOD", "label": "Cash and cash equivalents" } }, "en": { "role": { "documentation": "The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]" } } }, "auth_ref": [ "r24", "r40", "r80", "r123" ] }, "ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments", "crdr": "debit", "calculation": { "http://biolinerx.com/role/CondensedConsolidatedInterimCashFlowStatements": { "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://biolinerx.com/role/CondensedConsolidatedInterimCashFlowStatements" ], "lang": { "en-us": { "role": { "label": "Investments in short-term deposits" } }, "en": { "role": { "documentation": "The cash inflow (outflow) due to a decrease (increase) in short-term deposits and investments." } } }, "auth_ref": [ "r241" ] }, "ifrs-full_CashFlowsFromUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CashFlowsFromUsedInFinancingActivities", "crdr": "debit", "calculation": { "http://biolinerx.com/role/CondensedConsolidatedInterimCashFlowStatements": { "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalents", "weight": 1.0, "order": 20.0 } }, "presentation": [ "http://biolinerx.com/role/CondensedConsolidatedInterimCashFlowStatements" ], "lang": { "en-us": { "role": { "label": "Cash flows from (used in) financing activities", "totalLabel": "Net cash provided by (used in) financing activities" } }, "en": { "role": { "documentation": "The cash flows from (used in) financing activities, which are activities that result in changes in the size and composition of the contributed equity and borrowings of the entity, from continuing and discontinued operations." } } }, "auth_ref": [ "r20", "r25" ] }, "ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CashFlowsFromUsedInFinancingActivitiesAbstract", "presentation": [ "http://biolinerx.com/role/CondensedConsolidatedInterimCashFlowStatements" ], "lang": { "en-us": { "role": { "label": "CASH FLOWS - FINANCING ACTIVITIES" } } }, "auth_ref": [] }, "ifrs-full_CashFlowsFromUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CashFlowsFromUsedInInvestingActivities", "crdr": "debit", "calculation": { "http://biolinerx.com/role/CondensedConsolidatedInterimCashFlowStatements": { "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalents", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://biolinerx.com/role/CondensedConsolidatedInterimCashFlowStatements" ], "lang": { "en-us": { "role": { "label": "Cash flows from (used in) investing activities", "totalLabel": "Net cash provided by (used in) investing activities" } }, "en": { "role": { "documentation": "The cash flows from (used in) investing activities, which are the acquisition and disposal of long-term assets and other investments not included in cash equivalents, from continuing and discontinued operations." } } }, "auth_ref": [ "r20", "r25" ] }, "ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CashFlowsFromUsedInInvestingActivitiesAbstract", "presentation": [ "http://biolinerx.com/role/CondensedConsolidatedInterimCashFlowStatements" ], "lang": { "en-us": { "role": { "label": "CASH FLOWS - INVESTING ACTIVITIES" } } }, "auth_ref": [] }, "ifrs-full_CashFlowsFromUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CashFlowsFromUsedInOperatingActivities", "calculation": { "http://biolinerx.com/role/CondensedConsolidatedInterimCashFlowStatements": { "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalents", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://biolinerx.com/role/CondensedConsolidatedInterimCashFlowStatements" ], "lang": { "en-us": { "role": { "label": "Cash flows from (used in) operating activities", "totalLabel": "Net cash used in operating activities" } } }, "auth_ref": [ "r20", "r25" ] }, "ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CashFlowsFromUsedInOperatingActivitiesAbstract", "presentation": [ "http://biolinerx.com/role/CondensedConsolidatedInterimCashFlowStatements" ], "lang": { "en-us": { "role": { "label": "CASH FLOWS - OPERATING ACTIVITIES" } } }, "auth_ref": [] }, "ifrs-full_CategoriesOfRelatedPartiesAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CategoriesOfRelatedPartiesAxis", "presentation": [ "http://biolinerx.com/role/AGREEMENTWITHHEMISPHERIANFORDEVELOPMENTOFGLIX1NarrativeDetails", "http://biolinerx.com/role/At-the-marketAtmSalesAgreementWithBtigDetails", "http://biolinerx.com/role/EQUITYFINANCINGNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Categories of related parties [axis]", "verboseLabel": "Categories of related parties [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r5", "r85" ] }, "ifrs-full_CategoriesOfRelatedPartiesDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CategoriesOfRelatedPartiesDomain", "presentation": [ "http://biolinerx.com/role/AGREEMENTWITHHEMISPHERIANFORDEVELOPMENTOFGLIX1NarrativeDetails", "http://biolinerx.com/role/At-the-marketAtmSalesAgreementWithBtigDetails", "http://biolinerx.com/role/EQUITYFINANCINGNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Categories of related parties [domain]" } }, "en": { "role": { "documentation": "This member stands for the standard value for the 'Categories of related parties' axis if no other member is used." } } }, "auth_ref": [ "r5", "r85" ] }, "ecd_ChangedPeerGroupFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "ChangedPeerGroupFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Changed Peer Group, Footnote [Text Block]", "terseLabel": "Changed Peer Group, Footnote" } } }, "auth_ref": [ "r202" ] }, "ifrs-full_ChangesInEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ChangesInEquityAbstract", "presentation": [ "http://biolinerx.com/role/CondensedInterimStatementsOfChangesInEquity" ], "lang": { "en-us": { "role": { "label": "CHANGES FOR", "terseLabel": "CHANGES FOR THE PERIOD:" } } }, "auth_ref": [] }, "blrx_ChangesInFairValueRecordedAsANonoperatingIncome": { "xbrltype": "monetaryItemType", "nsuri": "http://biolinerx.com/20260630", "localname": "ChangesInFairValueRecordedAsANonoperatingIncome", "crdr": "credit", "presentation": [ "http://biolinerx.com/role/EQUITYFINANCINGNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "The gains (losses) resulting from change in the fair value of derivatives recognised in profit or loss.", "label": "Changes In Fair Value Recorded As A Non-operating Income", "terseLabel": "Changes in fair value recorded as non-operating income" } } }, "auth_ref": [] }, "blrx_ChangesInFairValueThroughProfitOrLossWarrantsMeasured": { "xbrltype": "monetaryItemType", "nsuri": "http://biolinerx.com/20260630", "localname": "ChangesInFairValueThroughProfitOrLossWarrantsMeasured", "crdr": "credit", "presentation": [ "http://biolinerx.com/role/FAIRVALUEMEASUREMENTOFWARRANTSUSINGSIGNIFICANTUNOBSERVABLEINPUTSLEVEL3Details" ], "lang": { "en-us": { "role": { "label": "Changes In Fair Value Through Profit Or Loss Warrants Measured", "documentation": "Net changes in fair value recognized in profit or loss for warrants.", "terseLabel": "Changes in fair value through profit and loss" } } }, "auth_ref": [] }, "blrx_ChangesInOperatingAssetsAndLiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://biolinerx.com/20260630", "localname": "ChangesInOperatingAssetsAndLiabilitiesAbstract", "presentation": [ "http://biolinerx.com/role/CondensedConsolidatedInterimCashFlowStatements" ], "lang": { "en-us": { "role": { "label": "Changes In Operating Assets And Liabilities [Abstract]", "verboseLabel": "Changes in operating asset and liability items:" } } }, "auth_ref": [] }, "blrx_ChangesInRightOfUseAssetAndLeaseLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://biolinerx.com/20260630", "localname": "ChangesInRightOfUseAssetAndLeaseLiabilities", "crdr": "credit", "presentation": [ "http://biolinerx.com/role/CondensedConsolidatedInterimCashFlowStatements" ], "lang": { "en-us": { "role": { "documentation": "Changes in right-of-use asset and lease liabilities.", "label": "Changes In Right Of Use Asset And Lease Liabilities", "terseLabel": "Changes in right-of-use asset and lease liabilities", "verboseLabel": "Acquisition of right-of-use asset" } } }, "auth_ref": [] }, "ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]", "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year" } } }, "auth_ref": [ "r199" ] }, "ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]", "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested" } } }, "auth_ref": [ "r197" ] }, "ifrs-full_ClassesOfFinancialInstrumentsAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ClassesOfFinancialInstrumentsAxis", "presentation": [ "http://biolinerx.com/role/EQUITYFINANCINGNarrativeDetails", "http://biolinerx.com/role/SUBSEQUENTEVENTNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Classes of financial instruments [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r59", "r60", "r61", "r62", "r99", "r100" ] }, "ifrs-full_ClassesOfFinancialInstrumentsDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ClassesOfFinancialInstrumentsDomain", "presentation": [ "http://biolinerx.com/role/EQUITYFINANCINGNarrativeDetails", "http://biolinerx.com/role/SUBSEQUENTEVENTNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Classes of financial instruments [domain]" } }, "en": { "role": { "documentation": "This member stands for aggregated classes of financial instruments. Financial instruments are contracts that give rise to a financial asset of one entity and a financial liability or equity instrument of another entity. It also represents the standard value for the 'Classes of financial instruments' axis if no other member is used. [Refer: Financial assets; Financial liabilities]" } } }, "auth_ref": [ "r59", "r60", "r61", "r62", "r99", "r100" ] }, "ecd_CoSelectedMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "CoSelectedMeasureAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Company Selected Measure Amount", "terseLabel": "Company Selected Measure Amount" } } }, "auth_ref": [ "r203" ] }, "ecd_CoSelectedMeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "CoSelectedMeasureName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Company Selected Measure Name", "terseLabel": "Company Selected Measure Name" } } }, "auth_ref": [ "r203" ] }, "blrx_CollaborationAndShareholdersAgreementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://biolinerx.com/20260630", "localname": "CollaborationAndShareholdersAgreementLineItems", "presentation": [ "http://biolinerx.com/role/AGREEMENTWITHHEMISPHERIANFORDEVELOPMENTOFGLIX1NarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Collaboration And Shareholders Agreement [Line Items]" } } }, "auth_ref": [] }, "blrx_CollaborationAndShareholdersAgreementTable": { "xbrltype": "stringItemType", "nsuri": "http://biolinerx.com/20260630", "localname": "CollaborationAndShareholdersAgreementTable", "presentation": [ "http://biolinerx.com/role/AGREEMENTWITHHEMISPHERIANFORDEVELOPMENTOFGLIX1NarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Collaboration And Shareholders Agreement [Table]" } } }, "auth_ref": [] }, "blrx_CollaborationTransactionAxis": { "xbrltype": "stringItemType", "nsuri": "http://biolinerx.com/20260630", "localname": "CollaborationTransactionAxis", "presentation": [ "http://biolinerx.com/role/AGREEMENTWITHHEMISPHERIANFORDEVELOPMENTOFGLIX1NarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Collaboration Transaction [Axis]" } } }, "auth_ref": [] }, "blrx_CollaborationTransactionDomain": { "xbrltype": "domainItemType", "nsuri": "http://biolinerx.com/20260630", "localname": "CollaborationTransactionDomain", "presentation": [ "http://biolinerx.com/role/AGREEMENTWITHHEMISPHERIANFORDEVELOPMENTOFGLIX1NarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Collaboration Transaction [Domain]" } } }, "auth_ref": [] }, "blrx_CommitmentsAndContingentLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://biolinerx.com/20260630", "localname": "CommitmentsAndContingentLiabilities", "crdr": "credit", "calculation": { "http://biolinerx.com/role/CondensedConsolidatedInterimStatementsOfFinancialPosition": { "parentTag": "ifrs-full_EquityAndLiabilities", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://biolinerx.com/role/CondensedConsolidatedInterimStatementsOfFinancialPosition" ], "lang": { "en-us": { "role": { "documentation": "Commitment and contingent liabilities.", "label": "COMMITMENTS AND CONTINGENT LIABILITIES", "terseLabel": "COMMITMENTS AND CONTINGENT LIABILITIES" } } }, "auth_ref": [] }, "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]", "terseLabel": "Compensation Actually Paid vs. Company Selected Measure" } } }, "auth_ref": [ "r208" ] }, "ecd_CompActuallyPaidVsNetIncomeTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "CompActuallyPaidVsNetIncomeTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Net Income [Text Block]", "terseLabel": "Compensation Actually Paid vs. Net Income" } } }, "auth_ref": [ "r207" ] }, "ecd_CompActuallyPaidVsOtherMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "CompActuallyPaidVsOtherMeasureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Other Measure [Text Block]", "terseLabel": "Compensation Actually Paid vs. Other Measure" } } }, "auth_ref": [ "r209" ] }, "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]", "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return" } } }, "auth_ref": [ "r206" ] }, "ifrs-full_ComponentsOfEquityAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ComponentsOfEquityAxis", "presentation": [ "http://biolinerx.com/role/CondensedInterimStatementsOfChangesInEquity" ], "lang": { "en-us": { "role": { "label": "Components of equity [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r116" ] }, "ifrs-full_ComponentsOfEquityDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ComponentsOfEquityDomain", "presentation": [ "http://biolinerx.com/role/CondensedInterimStatementsOfChangesInEquity" ], "lang": { "en-us": { "role": { "label": "Components of equity [domain]" } }, "en": { "role": { "documentation": "This member stands for the residual interest in the assets of the entity after deducting all its liabilities. It also represents the standard value for the 'Components of equity' axis if no other member is used." } } }, "auth_ref": [ "r116" ] }, "ifrs-full_ComprehensiveIncome": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ComprehensiveIncome", "crdr": "credit", "calculation": { "http://biolinerx.com/role/CondensedConsolidatedInterimStatementsOfComprehensiveLoss__1": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://biolinerx.com/role/CondensedConsolidatedInterimStatementsOfComprehensiveLoss", "http://biolinerx.com/role/CondensedInterimStatementsOfChangesInEquity" ], "lang": { "en-us": { "role": { "label": "Comprehensive income", "terseLabel": "Net loss for the period", "totalLabel": "Total comprehensive income", "verboseLabel": "Comprehensive loss (income) for the period" } }, "en": { "role": { "documentation": "The amount of change in equity resulting from transactions and other events, other than those changes resulting from transactions with owners in their capacity as owners." } } }, "auth_ref": [ "r27", "r29", "r38", "r87", "r96", "r113", "r136", "r147" ] }, "ifrs-full_ComprehensiveIncomeAttributableToNoncontrollingInterests": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ComprehensiveIncomeAttributableToNoncontrollingInterests", "crdr": "credit", "calculation": { "http://biolinerx.com/role/CondensedConsolidatedInterimStatementsOfComprehensiveLoss__1": { "parentTag": "ifrs-full_ComprehensiveIncome", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://biolinerx.com/role/CondensedConsolidatedInterimStatementsOfComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Comprehensive income, attributable to non-controlling interests", "terseLabel": "To non-controlling interests" } }, "en": { "role": { "documentation": "The amount of comprehensive income attributable to non-controlling interests. [Refer: Comprehensive income; Non-controlling interests]" } } }, "auth_ref": [ "r113", "r137" ] }, "ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ComprehensiveIncomeAttributableToOwnersOfParent", "crdr": "credit", "calculation": { "http://biolinerx.com/role/CondensedConsolidatedInterimStatementsOfComprehensiveLoss__1": { "parentTag": "ifrs-full_ComprehensiveIncome", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://biolinerx.com/role/CondensedConsolidatedInterimStatementsOfComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Comprehensive income, attributable to owners of parent", "terseLabel": "To owners of the Company" } }, "en": { "role": { "documentation": "The amount of comprehensive income attributable to owners of the parent. [Refer: Comprehensive income]" } } }, "auth_ref": [ "r113", "r138" ] }, "ifrs-full_CostOfSales": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CostOfSales", "crdr": "debit", "calculation": { "http://biolinerx.com/role/CondensedConsolidatedInterimStatementsOfComprehensiveLoss": { "parentTag": "ifrs-full_GrossProfit", "weight": -1.0, "order": 10.0 } }, "presentation": [ "http://biolinerx.com/role/CondensedConsolidatedInterimStatementsOfComprehensiveLoss" ], "lang": { "en-us": { "role": { "negatedLabel": "COST OF REVENUES", "label": "Cost of sales", "totalLabel": "Cost of revenues", "verboseLabel": "Cost of sales", "negatedTerseLabel": "Cost of sales" } } }, "auth_ref": [ "r112", "r141" ] }, "srt_CurrencyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2025", "localname": "CurrencyAxis", "presentation": [ "http://biolinerx.com/role/ShareholdersEquityScheduleOfShareCapitalDetails" ], "lang": { "en-us": { "role": { "label": "Foreign Currency [Axis]", "verboseLabel": "Currency [Axis]" } } }, "auth_ref": [] }, "ifrs-full_CurrentAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CurrentAssets", "crdr": "debit", "calculation": { "http://biolinerx.com/role/CondensedConsolidatedInterimStatementsOfFinancialPosition": { "parentTag": "ifrs-full_Assets", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://biolinerx.com/role/CondensedConsolidatedInterimStatementsOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Current assets", "totalLabel": "Total current assets" } }, "en": { "role": { "documentation": "The amount of assets that the entity (a) expects to realise or intends to sell or consume in its normal operating cycle; (b) holds primarily for the purpose of trading; (c) expects to realise within twelve months after the reporting period; or (d) classifies as cash or cash equivalents (as defined in IAS 7) unless the asset is restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period. [Refer: Assets]" } } }, "auth_ref": [ "r34", "r127", "r147" ] }, "ifrs-full_CurrentAssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CurrentAssetsAbstract", "presentation": [ "http://biolinerx.com/role/CondensedConsolidatedInterimStatementsOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "CURRENT ASSETS" } } }, "auth_ref": [] }, "ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings", "crdr": "credit", "calculation": { "http://biolinerx.com/role/CondensedConsolidatedInterimStatementsOfFinancialPosition": { "parentTag": "ifrs-full_CurrentLiabilities", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://biolinerx.com/role/CondensedConsolidatedInterimStatementsOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Current maturities of long-term loan" } }, "en": { "role": { "documentation": "The amount of current borrowings and current portion of non-current borrowings. [Refer: Borrowings]" } } }, "auth_ref": [ "r251" ] }, "ifrs-full_CurrentContractLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CurrentContractLiabilities", "crdr": "credit", "calculation": { "http://biolinerx.com/role/CondensedConsolidatedInterimStatementsOfFinancialPosition": { "parentTag": "ifrs-full_CurrentLiabilities", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://biolinerx.com/role/CondensedConsolidatedInterimStatementsOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Current contract liabilities", "verboseLabel": "Contract liabilities" } }, "en": { "role": { "documentation": "The amount of current contract liabilities. [Refer: Contract liabilities]" } } }, "auth_ref": [ "r47" ] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://biolinerx.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "ifrs-full_CurrentLeaseLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CurrentLeaseLiabilities", "crdr": "credit", "calculation": { "http://biolinerx.com/role/CondensedConsolidatedInterimStatementsOfFinancialPosition": { "parentTag": "ifrs-full_CurrentLiabilities", "weight": 1.0, "order": 20.0 } }, "presentation": [ "http://biolinerx.com/role/CondensedConsolidatedInterimStatementsOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Lease liabilities", "terseLabel": "Current maturities of lease liabilities" } }, "en": { "role": { "documentation": "The amount of current lease liabilities. [Refer: Lease liabilities]" } } }, "auth_ref": [ "r49" ] }, "ifrs-full_CurrentLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CurrentLiabilities", "crdr": "credit", "calculation": { "http://biolinerx.com/role/CondensedConsolidatedInterimStatementsOfFinancialPosition": { "parentTag": "ifrs-full_Liabilities", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://biolinerx.com/role/CondensedConsolidatedInterimStatementsOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Current liabilities", "totalLabel": "Total current liabilities" } }, "en": { "role": { "documentation": "The amount of liabilities that: (a) the entity expects to settle in its normal operating cycle; (b) the entity holds primarily for the purpose of trading; (c) are due to be settled within twelve months after the reporting period; or (d) the entity does not have the right at the end of the reporting period to defer settlement for at least twelve months after the reporting period." } } }, "auth_ref": [ "r36", "r128", "r147" ] }, "ifrs-full_CurrentLiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CurrentLiabilitiesAbstract", "presentation": [ "http://biolinerx.com/role/CondensedConsolidatedInterimStatementsOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "CURRENT LIABILITIES" } } }, "auth_ref": [] }, "ifrs-full_CurrentPrepaidExpenses": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CurrentPrepaidExpenses", "crdr": "debit", "calculation": { "http://biolinerx.com/role/CondensedConsolidatedInterimStatementsOfFinancialPosition": { "parentTag": "ifrs-full_CurrentAssets", "weight": 1.0, "order": 20.0 } }, "presentation": [ "http://biolinerx.com/role/CondensedConsolidatedInterimStatementsOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Prepaid expenses" } }, "en": { "role": { "documentation": "The amount recognised as a current asset for expenditures made prior to the period when the economic benefit will be realised." } } }, "auth_ref": [ "r250" ] }, "blrx_DayOneLossOnWarrantsMeasured": { "xbrltype": "monetaryItemType", "nsuri": "http://biolinerx.com/20260630", "localname": "DayOneLossOnWarrantsMeasured", "crdr": "credit", "presentation": [ "http://biolinerx.com/role/FAIRVALUEMEASUREMENTOFWARRANTSUSINGSIGNIFICANTUNOBSERVABLEINPUTSLEVEL3Details" ], "lang": { "en-us": { "role": { "label": "Day One Loss On Warrants Measured", "documentation": "Initial loss recognized at issuance of warrants.", "terseLabel": "Day One loss" } } }, "auth_ref": [] }, "blrx_DefinitiveAgreementInstitutionalInvestorMember": { "xbrltype": "domainItemType", "nsuri": "http://biolinerx.com/20260630", "localname": "DefinitiveAgreementInstitutionalInvestorMember", "presentation": [ "http://biolinerx.com/role/SUBSEQUENTEVENTNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Definitive Agreement Institutional Investor [Member]", "documentation": "This member stands for definitive agreement institutional investor.", "verboseLabel": "Definitive agreement institutional investor [Member]" } } }, "auth_ref": [] }, "blrx_DescriptionOfAccountingPolicyForChangeInAccountingPolicyAndDisclosuresExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "http://biolinerx.com/20260630", "localname": "DescriptionOfAccountingPolicyForChangeInAccountingPolicyAndDisclosuresExplanatory", "presentation": [ "http://biolinerx.com/role/MATERIALACCOUNTINGPOLICIESPolicies" ], "lang": { "en-us": { "role": { "label": "Description Of Accounting Policy For Change In Accounting Policy And Disclosures Explanatory", "terseLabel": "New International Financial Reporting Standards, amendments to standards and new interpretations", "documentation": "The description of the entity's accounting policy for changes in accounting policies and disclosures.", "verboseLabel": "New international financial reporting standards, amendments to standards and new interpretations" } } }, "auth_ref": [] }, "blrx_DescriptionOfAccountingPolicyForGeneralDisclosuresExplanatoryPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://biolinerx.com/20260630", "localname": "DescriptionOfAccountingPolicyForGeneralDisclosuresExplanatoryPolicyTextBlock", "presentation": [ "http://biolinerx.com/role/MATERIALACCOUNTINGPOLICIESPolicies" ], "lang": { "en-us": { "role": { "label": "Description Of Accounting Policy For General Disclosures Explanatory [Policy Text Block]", "documentation": "The description of the entity's accounting policy for general disclosures.", "terseLabel": "General" } } }, "auth_ref": [] }, "ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted": { "xbrltype": "percentItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DescriptionOfExpectedVolatilityShareOptionsGranted", "presentation": [ "http://biolinerx.com/role/EQUITYFINANCINGNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Expected volatility (%)", "verboseLabel": "Average standard deviation" } }, "en": { "role": { "documentation": "The expected volatility of the share price used to calculate the fair value of the share options granted. Expected volatility is a measure of the amount by which a price is expected to fluctuate during a period. The measure of volatility used in option pricing models is the annualised standard deviation of the continuously compounded rates of return on the share over a period of time." } } }, "auth_ref": [ "r54" ] }, "ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted": { "xbrltype": "percentItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DescriptionOfRiskFreeInterestRateShareOptionsGranted", "presentation": [ "http://biolinerx.com/role/EQUITYFINANCINGNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Risk-free interest rate (%)", "verboseLabel": "Risk-free interest rate" } }, "en": { "role": { "documentation": "The implied yield currently available on zero-coupon government issues of the country in whose currency the exercise price for share options granted is expressed, with a remaining term equal to the expected term of the option being valued (based on the option's remaining contractual life and taking into account the effects of expected early exercise). [Refer: Government [member]]" } } }, "auth_ref": [ "r54" ] }, "ifrs-full_DilutedEarningsLossPerShare": { "xbrltype": "perShareItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DilutedEarningsLossPerShare", "presentation": [ "http://biolinerx.com/role/CondensedConsolidatedInterimStatementsOfComprehensiveLoss" ], "lang": { "en-us": { "role": { "commentaryGuidance": "The reported value should be tagged twice, with both this element and the element \u2018Basic earnings (loss) per share\u2019 when: (a) basic and diluted earnings per share are equal; and (b) an entity presents one line item to accomplish the dual presentation requirement of paragraph 67 of IAS 33.", "label": "Diluted earnings (loss) per share", "totalLabel": "Total diluted earnings (loss) per share", "verboseLabel": "EARNINGS (LOSS) PER ORDINARY SHARE \u2013 DILUTED ATTRIBUTABLE TO OWNERS OF THE COMPANY" } }, "en": { "role": { "documentation": "The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator), divided by the weighted average number of ordinary shares outstanding during the period (the denominator), both adjusted for the effects of all dilutive potential ordinary shares. [Refer: Ordinary shares [member]; Weighted average [member]]" } } }, "auth_ref": [ "r8", "r9" ] }, "blrx_DisclosureOfBasisOfPreparationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://biolinerx.com/20260630", "localname": "DisclosureOfBasisOfPreparationAbstract", "lang": { "en-us": { "role": { "label": "Disclosure of basis of preparation [Abstract]" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory", "presentation": [ "http://biolinerx.com/role/BasisOfPreparation" ], "lang": { "en-us": { "role": { "label": "BASIS OF PREPARATION" } } }, "auth_ref": [ "r248" ] }, "ifrs-full_DisclosureOfClassesOfShareCapitalAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfClassesOfShareCapitalAbstract", "lang": { "en-us": { "role": { "label": "Disclosure of classes of share capital [abstract]" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfClassesOfShareCapitalExplanatory", "presentation": [ "http://biolinerx.com/role/ShareholdersEquityTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Share Capital", "verboseLabel": "Schedule of Share Capital is Composed of Ordinary Shares" } }, "en": { "role": { "documentation": "The disclosure of classes of share capital. [Refer: Classes of share capital [domain]]" } } }, "auth_ref": [ "r77", "r108", "r133" ] }, "blrx_DisclosureOfEquityFinancingAbstract": { "xbrltype": "stringItemType", "nsuri": "http://biolinerx.com/20260630", "localname": "DisclosureOfEquityFinancingAbstract", "lang": { "en-us": { "role": { "label": "Disclosure Of Equity Financing [Abstract]" } } }, "auth_ref": [] }, "blrx_DisclosureOfEquityFinancingExplanatoryTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://biolinerx.com/20260630", "localname": "DisclosureOfEquityFinancingExplanatoryTextBlock", "presentation": [ "http://biolinerx.com/role/EQUITYFINANCING" ], "lang": { "en-us": { "role": { "label": "Disclosure Of Equity Financing Explanatory [Text Block]", "documentation": "The entire disclosure of equity financing.", "terseLabel": "FINANCINGS" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfFairValueMeasurementExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfFairValueMeasurementExplanatory", "presentation": [ "http://biolinerx.com/role/FAIRVALUEMEASUREMENTOFWARRANTSUSINGSIGNIFICANTUNOBSERVABLEINPUTSLEVEL3" ], "lang": { "en-us": { "role": { "label": "Disclosure of fair value measurement [text block]", "terseLabel": "FAIR VALUE MEASUREMENT OF WARRANTS USING SIGNIFICANT UNOBSERVABLE INPUTS (LEVEL 3)" } }, "en": { "role": { "documentation": "The entire disclosure for fair value measurement." } } }, "auth_ref": [ "r46" ] }, "ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfFairValueMeasurementOfLiabilitiesLineItems", "presentation": [ "http://biolinerx.com/role/FAIRVALUEMEASUREMENTOFWARRANTSUSINGSIGNIFICANTUNOBSERVABLEINPUTSLEVEL3Details" ], "lang": { "en-us": { "role": { "label": "Disclosure of fair value measurement of liabilities [line items]" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfFairValueMeasurementOfLiabilitiesTable", "presentation": [ "http://biolinerx.com/role/FAIRVALUEMEASUREMENTOFWARRANTSUSINGSIGNIFICANTUNOBSERVABLEINPUTSLEVEL3Details" ], "lang": { "en": { "role": { "documentation": "Schedule disclosing information related to the fair value measurement of liabilities." } } }, "auth_ref": [ "r45", "r104" ] }, "ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory", "presentation": [ "http://biolinerx.com/role/GeneralInformation" ], "lang": { "en-us": { "role": { "label": "GENERAL INFORMATION" } }, "en": { "role": { "documentation": "The entire disclosure for general information about financial statements." } } }, "auth_ref": [ "r73", "r118" ] }, "blrx_DisclosureOfGeneralInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://biolinerx.com/20260630", "localname": "DisclosureOfGeneralInformationAbstract", "lang": { "en-us": { "role": { "label": "Disclosure of general information [Abstract]", "verboseLabel": "General Information Narrative" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory", "presentation": [ "http://biolinerx.com/role/ShareholdersEquityTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Assumptions Used to Value Options" } }, "en": { "role": { "documentation": "The disclosure of information about indirect, by reference to the fair value of the equity instruments granted, measurement of the fair value of goods or services received as consideration for the entity's share options." } } }, "auth_ref": [ "r55" ] }, "blrx_DisclosureOfIssuancesOfShareCapitalAbstract": { "xbrltype": "stringItemType", "nsuri": "http://biolinerx.com/20260630", "localname": "DisclosureOfIssuancesOfShareCapitalAbstract", "lang": { "en-us": { "role": { "label": "Disclosure Of Issuances Of Share Capital [Abstract]", "verboseLabel": "Disclosure of issuances of share capital and warrants [Abstract]" } } }, "auth_ref": [] }, "blrx_DisclosureOfMarketAtmSalesAgreementWithBtigExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "http://biolinerx.com/20260630", "localname": "DisclosureOfMarketAtmSalesAgreementWithBtigExplanatory", "presentation": [ "http://biolinerx.com/role/At-the-marketAtmSalesAgreementWithBtig" ], "lang": { "en-us": { "role": { "documentation": "Disclosure Of At The Market Atm Sales Agreement With Btig Explanatory .", "label": "Disclosure Of Market Atm Sales Agreement With Btig Explanatory", "terseLabel": "AT-THE-MARKET (\u201cATM\u201d) SALES AGREEMENT WITH HCW", "verboseLabel": "AT-THE-MARKET (\"ATM\") SALES AGREEMENT WITH BTIG" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfMaterialAccountingPolicyInformationExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfMaterialAccountingPolicyInformationExplanatory", "presentation": [ "http://biolinerx.com/role/SignificantAccountingPolicies" ], "lang": { "en-us": { "role": { "label": "SIGNIFICANT ACCOUNTING POLICIES", "terseLabel": "MATERIAL ACCOUNTING POLICIES" } }, "en": { "role": { "documentation": "The entire disclosure of material accounting policy information applied by the entity." } } }, "auth_ref": [ "r81", "r110", "r117" ] }, "ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract", "lang": { "en-us": { "role": { "label": "Disclosure of non-adjusting events after reporting period [abstract]" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfNonadjustingEventsAfterReportingPeriodExplanatory", "presentation": [ "http://biolinerx.com/role/SUBSEQUENTEVENTS" ], "lang": { "en-us": { "role": { "label": "Disclosure of non-adjusting events after reporting period [text block]", "terseLabel": "SUBSEQUENT EVENTS" } }, "en": { "role": { "documentation": "The disclosure of non-adjusting events after the reporting period. [Refer: Non-adjusting events after reporting period [domain]]" } } }, "auth_ref": [ "r0", "r82" ] }, "ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems", "presentation": [ "http://biolinerx.com/role/SUBSEQUENTEVENTNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of non-adjusting events after reporting period [line items]" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfNonadjustingEventsAfterReportingPeriodTable", "presentation": [ "http://biolinerx.com/role/SUBSEQUENTEVENTNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of non-adjusting events after reporting period [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to non-adjusting events after the reporting period." } } }, "auth_ref": [ "r0", "r82" ] }, "ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory", "presentation": [ "http://biolinerx.com/role/ShareholdersEquityTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Amounts Outstanding Under Employee Share Incentive Plan" } }, "en": { "role": { "documentation": "The disclosure of the number and weighted average exercise prices of share options. [Refer: Weighted average [member]]" } } }, "auth_ref": [ "r51", "r97" ] }, "ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory", "presentation": [ "http://biolinerx.com/role/ShareholdersEquityTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Options Outstanding by Exercise Price Range" } }, "en": { "role": { "documentation": "The disclosure of the number and weighted average remaining contractual life of outstanding share options. [Refer: Weighted average [member]]" } } }, "auth_ref": [ "r52" ] }, "ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory", "presentation": [ "http://biolinerx.com/role/ShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Disclosure of share capital, reserves and other equity interest [text block]", "terseLabel": "SHAREHOLDERS' EQUITY" } }, "en": { "role": { "documentation": "The entire disclosure for share capital, reserves and other equity interest." } } }, "auth_ref": [ "r78", "r109", "r134" ] }, "blrx_DisclosureOfSignificantAccountingPoliciesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://biolinerx.com/20260630", "localname": "DisclosureOfSignificantAccountingPoliciesAbstract", "lang": { "en-us": { "role": { "label": "Disclosure of significant accounting policies [Abstract]" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesAbstract", "lang": { "en-us": { "role": { "label": "Disclosure of significant unobservable inputs used in fair value measurement of liabilities [abstract]" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesExplanatory", "presentation": [ "http://biolinerx.com/role/FAIRVALUEMEASUREMENTOFWARRANTSUSINGSIGNIFICANTUNOBSERVABLEINPUTSLEVEL3Tables" ], "lang": { "en-us": { "role": { "label": "Disclosure of significant unobservable inputs used in fair value measurement of liabilities [text block]", "terseLabel": "Schedule of Significant Unobservable Inputs Used in Fair Value Measurement of Liabilities" } }, "en": { "role": { "documentation": "The disclosure of significant inputs for which market data are not available and that are developed using the best information available about the assumptions that market participants would use when measuring the fair value of liabilities." } } }, "auth_ref": [ "r43" ] }, "ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems", "presentation": [ "http://biolinerx.com/role/At-the-marketAtmSalesAgreementWithBtigDetails", "http://biolinerx.com/role/EQUITYFINANCINGNarrativeDetails", "http://biolinerx.com/role/ShareholdersEquityScheduleOfShareCapitalDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of terms and conditions of share-based payment arrangement [line items]" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable", "presentation": [ "http://biolinerx.com/role/At-the-marketAtmSalesAgreementWithBtigDetails", "http://biolinerx.com/role/EQUITYFINANCINGNarrativeDetails", "http://biolinerx.com/role/ShareholdersEquityScheduleOfShareCapitalDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of terms and conditions of share-based payment arrangement [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to terms and conditions of share-based payment arrangements." } } }, "auth_ref": [ "r53", "r98" ] }, "blrx_DocumentAndEntityInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://biolinerx.com/20260630", "localname": "DocumentAndEntityInformationAbstract", "lang": { "en-us": { "role": { "label": "Document And Entity Information [Abstract]", "verboseLabel": "Document And Entity Information" } } }, "auth_ref": [] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://biolinerx.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://biolinerx.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentPeriodEndDate", "presentation": [ "http://biolinerx.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentType", "presentation": [ "http://biolinerx.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]", "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year" } } }, "auth_ref": [ "r201" ] }, "ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "EffectOfExchangeRateChangesOnCashAndCashEquivalents", "crdr": "debit", "presentation": [ "http://biolinerx.com/role/CondensedConsolidatedInterimCashFlowStatements" ], "lang": { "en-us": { "role": { "label": "EXCHANGE DIFFERENCES ON CASH AND CASH EQUIVALENTS" } }, "en": { "role": { "documentation": "The effect of exchange rate changes on cash and cash equivalents held or due in a foreign currency. [Refer: Cash and cash equivalents]" } } }, "auth_ref": [ "r22", "r23" ] }, "us-gaap_EmployeeStockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "EmployeeStockOptionMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Employee Stock Option [Member]", "terseLabel": "Employee Stock Option" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityAddressAddressLine1", "presentation": [ "http://biolinerx.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityAddressAddressLine2", "presentation": [ "http://biolinerx.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityAddressCountry", "presentation": [ "http://biolinerx.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://biolinerx.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityCentralIndexKey", "presentation": [ "http://biolinerx.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r159" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://biolinerx.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://biolinerx.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r159" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityFileNumber", "presentation": [ "http://biolinerx.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityFilerCategory", "presentation": [ "http://biolinerx.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r159" ] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityRegistrantName", "presentation": [ "http://biolinerx.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r159" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityShellCompany", "presentation": [ "http://biolinerx.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r159" ] }, "ecd_EqtyAwrdsAdjFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "EqtyAwrdsAdjFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Equity Awards Adjustments, Footnote [Text Block]", "terseLabel": "Equity Awards Adjustments, Footnote" } } }, "auth_ref": [ "r195" ] }, "ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]", "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table" } } }, "auth_ref": [ "r236" ] }, "ecd_EqtyAwrdsAdjsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "EqtyAwrdsAdjsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Equity Awards Adjustments [Member]", "terseLabel": "Equity Awards Adjustments" } } }, "auth_ref": [ "r236" ] }, "ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "EqtyAwrdsInSummryCompstnTblForAplblYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]", "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table" } } }, "auth_ref": [ "r236" ] }, "ifrs-full_Equity": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "Equity", "crdr": "credit", "calculation": { "http://biolinerx.com/role/CondensedConsolidatedInterimStatementsOfFinancialPosition": { "parentTag": "ifrs-full_EquityAndLiabilities", "weight": 1.0, "order": 20.0 } }, "presentation": [ "http://biolinerx.com/role/CondensedConsolidatedInterimStatementsOfFinancialPosition", "http://biolinerx.com/role/CondensedInterimStatementsOfChangesInEquity" ], "lang": { "en-us": { "role": { "periodEndLabel": "BALANCE", "periodStartLabel": "BALANCE", "label": "Equity", "totalLabel": "Total equity" } }, "en": { "role": { "documentation": "The amount of residual interest in the assets of the entity after deducting all its liabilities." } } }, "auth_ref": [ "r26", "r28", "r41", "r42", "r44", "r86", "r95", "r102", "r103", "r111", "r126", "r129" ] }, "ifrs-full_EquityAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "EquityAbstract", "presentation": [ "http://biolinerx.com/role/CondensedConsolidatedInterimStatementsOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "EQUITY" } } }, "auth_ref": [] }, "ifrs-full_EquityAndLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "EquityAndLiabilities", "crdr": "credit", "calculation": { "http://biolinerx.com/role/CondensedConsolidatedInterimStatementsOfFinancialPosition": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://biolinerx.com/role/CondensedConsolidatedInterimStatementsOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Equity and liabilities", "totalLabel": "Total liabilities and equity" } }, "en": { "role": { "documentation": "The amount of the entity's equity and liabilities. [Refer: Equity; Liabilities]" } } }, "auth_ref": [ "r126" ] }, "ifrs-full_EquityAndLiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "EquityAndLiabilitiesAbstract", "presentation": [ "http://biolinerx.com/role/CondensedConsolidatedInterimStatementsOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Liabilities and equity" } } }, "auth_ref": [] }, "ifrs-full_EquityAttributableToOwnersOfParent": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "EquityAttributableToOwnersOfParent", "crdr": "credit", "calculation": { "http://biolinerx.com/role/CondensedConsolidatedInterimStatementsOfFinancialPosition": { "parentTag": "ifrs-full_Equity", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://biolinerx.com/role/CondensedConsolidatedInterimStatementsOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Equity attributable to owners of parent", "totalLabel": "Total equity attributable to owners of the Company" } }, "en": { "role": { "documentation": "The amount of equity attributable to the owners of the parent. This specifically excludes non-controlling interest." } } }, "auth_ref": [ "r125" ] }, "ecd_EquityValuationAssumptionDifferenceFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "EquityValuationAssumptionDifferenceFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Equity Valuation Assumption Difference, Footnote [Text Block]", "terseLabel": "Equity Valuation Assumption Difference, Footnote" } } }, "auth_ref": [ "r205" ] }, "ecd_ErrCompAnalysisTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "ErrCompAnalysisTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Erroneous Compensation Analysis [Text Block]", "terseLabel": "Erroneous Compensation Analysis" } } }, "auth_ref": [ "r164", "r174", "r184", "r215" ] }, "ecd_ErrCompRecoveryTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "ErrCompRecoveryTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Erroneously Awarded Compensation Recovery [Table]", "terseLabel": "Erroneously Awarded Compensation Recovery" } } }, "auth_ref": [ "r161", "r171", "r181", "r212" ] }, "blrx_ExchangeDifferencesOnLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://biolinerx.com/20260630", "localname": "ExchangeDifferencesOnLeaseLiability", "crdr": "debit", "calculation": { "http://biolinerx.com/role/CondensedConsolidatedInterimCashFlowStatements": { "parentTag": "blrx_TotalIncomeAndExpenseNotInvolvingCashFlows", "weight": 1.0, "order": 50.0 } }, "presentation": [ "http://biolinerx.com/role/CondensedConsolidatedInterimCashFlowStatements" ], "lang": { "en-us": { "role": { "documentation": "Exchange Differences On Lease Liability.", "label": "Exchange differences on lease liability", "terseLabel": "Exchange differences on lease liabilities" } } }, "auth_ref": [] }, "ecd_ExecutiveCategoryAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "ExecutiveCategoryAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Executive Category [Axis]", "terseLabel": "Executive Category:" } } }, "auth_ref": [ "r211" ] }, "blrx_ExercisePriceOfShareIssued": { "xbrltype": "perShareItemType", "nsuri": "http://biolinerx.com/20260630", "localname": "ExercisePriceOfShareIssued", "presentation": [ "http://biolinerx.com/role/EQUITYFINANCINGNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Exercise price of shares issued.", "label": "Exercise Price Of Share Issued", "verboseLabel": "Share price per ADS", "terseLabel": "Exercise price of shares issued" } } }, "auth_ref": [] }, "blrx_ExercisePriceOfWarrants": { "xbrltype": "perShareItemType", "nsuri": "http://biolinerx.com/20260630", "localname": "ExercisePriceOfWarrants", "presentation": [ "http://biolinerx.com/role/EQUITYFINANCINGNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Exercise price of warrants.", "label": "Exercise price of warrants", "verboseLabel": "Exercise price of warrants" } } }, "auth_ref": [] }, "blrx_FairValueOfOrdinaryWarrantsAdjustedAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://biolinerx.com/20260630", "localname": "FairValueOfOrdinaryWarrantsAdjustedAmount", "crdr": "credit", "presentation": [ "http://biolinerx.com/role/EQUITYFINANCINGNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value Of Ordinary Warrants Adjusted Amount", "documentation": "Fair value of ordinary warrants adjusted amount.", "terseLabel": "Fair value of the ordinary warrants was adjusted amount" } } }, "auth_ref": [] }, "ifrs-full_FinanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "FinanceCosts", "crdr": "debit", "calculation": { "http://biolinerx.com/role/CondensedConsolidatedInterimStatementsOfComprehensiveLoss": { "parentTag": "ifrs-full_ProfitLoss", "weight": -1.0, "order": 20.0 } }, "presentation": [ "http://biolinerx.com/role/CondensedConsolidatedInterimStatementsOfComprehensiveLoss" ], "lang": { "en-us": { "role": { "negatedLabel": "FINANCIAL EXPENSES", "label": "Finance costs" } } }, "auth_ref": [ "r140" ] }, "ifrs-full_FinanceIncome": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "FinanceIncome", "crdr": "credit", "calculation": { "http://biolinerx.com/role/CondensedConsolidatedInterimStatementsOfComprehensiveLoss": { "parentTag": "ifrs-full_ProfitLoss", "weight": 1.0, "order": 30.0 } }, "presentation": [ "http://biolinerx.com/role/CondensedConsolidatedInterimStatementsOfComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "FINANCIAL INCOME" } } }, "auth_ref": [ "r253" ] }, "ifrs-full_FinancialLiabilitiesAtFairValue": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "FinancialLiabilitiesAtFairValue", "crdr": "credit", "presentation": [ "http://biolinerx.com/role/EQUITYFINANCINGNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Fair value of the warrants" } }, "en": { "role": { "documentation": "The fair value of financial liabilities. [Refer: At fair value [member]; Financial liabilities]" } } }, "auth_ref": [ "r58" ] }, "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount", "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount" } } }, "auth_ref": [ "r168", "r178", "r188", "r219" ] }, "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Expense of Enforcement, Amount", "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount" } } }, "auth_ref": [ "r168", "r178", "r188", "r219" ] }, "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Violation of Home Country Law, Amount", "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount" } } }, "auth_ref": [ "r168", "r178", "r188", "r219" ] }, "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery, Explanation of Impracticability [Text Block]", "terseLabel": "Forgone Recovery, Explanation of Impracticability" } } }, "auth_ref": [ "r168", "r178", "r188", "r219" ] }, "ecd_ForgoneRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "ForgoneRecoveryIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery, Individual Name", "terseLabel": "Name" } } }, "auth_ref": [ "r168", "r178", "r188", "r219" ] }, "ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]", "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year" } } }, "auth_ref": [ "r200" ] }, "ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "GainsLossesOnChangeInFairValueOfDerivatives", "crdr": "credit", "presentation": [ "http://biolinerx.com/role/EQUITYFINANCINGNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Change in fair value", "verboseLabel": "Change in fair value" } }, "en": { "role": { "documentation": "The gains (losses) resulting from change in the fair value of derivatives recognised in profit or loss. [Refer: Derivatives [member]]" } } }, "auth_ref": [ "r253" ] }, "blrx_GrossProceedsFromIssuingShares": { "xbrltype": "monetaryItemType", "nsuri": "http://biolinerx.com/20260630", "localname": "GrossProceedsFromIssuingShares", "crdr": "debit", "presentation": [ "http://biolinerx.com/role/At-the-marketAtmSalesAgreementWithBtigDetails" ], "lang": { "en-us": { "role": { "documentation": "The gross cash inflow from issuing shares after deducting fees and expenses.", "label": "Gross Proceeds From Issuing Shares", "terseLabel": "Gross proceeds from issuing shares" } } }, "auth_ref": [] }, "blrx_GrossProceedsFromSharesIssued": { "xbrltype": "monetaryItemType", "nsuri": "http://biolinerx.com/20260630", "localname": "GrossProceedsFromSharesIssued", "crdr": "debit", "presentation": [ "http://biolinerx.com/role/EQUITYFINANCINGNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Gross Proceeds From Shares Issued", "documentation": "Gross proceeds from shares issued.", "verboseLabel": "Gross proceeds", "terseLabel": "Issuance of share capital and warrants, net of issuance costs" } } }, "auth_ref": [] }, "ifrs-full_GrossProfit": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "GrossProfit", "crdr": "credit", "calculation": { "http://biolinerx.com/role/CondensedConsolidatedInterimStatementsOfComprehensiveLoss": { "parentTag": "ifrs-full_ProfitLossFromOperatingActivities", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://biolinerx.com/role/CondensedConsolidatedInterimStatementsOfComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Gross profit", "totalLabel": "GROSS PROFIT" } } }, "auth_ref": [ "r152" ] }, "blrx_HcwMember": { "xbrltype": "domainItemType", "nsuri": "http://biolinerx.com/20260630", "localname": "HcwMember", "presentation": [ "http://biolinerx.com/role/At-the-marketAtmSalesAgreementWithBtigDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for H.C. Wainwright & Co., LLC (\u201cHCW\u201d).", "label": "Hcw [Member]", "terseLabel": "HCW [Member]" } } }, "auth_ref": [] }, "blrx_HemispherianAsMember": { "xbrltype": "domainItemType", "nsuri": "http://biolinerx.com/20260630", "localname": "HemispherianAsMember", "presentation": [ "http://biolinerx.com/role/AGREEMENTWITHHEMISPHERIANFORDEVELOPMENTOFGLIX1NarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Hemispherian As [Member]" } } }, "auth_ref": [] }, "blrx_HighbridgeCapitalManagementLlcMember": { "xbrltype": "domainItemType", "nsuri": "http://biolinerx.com/20260630", "localname": "HighbridgeCapitalManagementLlcMember", "presentation": [ "http://biolinerx.com/role/EQUITYFINANCINGNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Highbridge Capital Management Llc [Member]", "documentation": "Highbridge Capital Management LLC [Member]" } } }, "auth_ref": [] }, "blrx_IncomeAndExpensesNotInvolvingCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://biolinerx.com/20260630", "localname": "IncomeAndExpensesNotInvolvingCashFlowsAbstract", "presentation": [ "http://biolinerx.com/role/CondensedConsolidatedInterimCashFlowStatements" ], "lang": { "en-us": { "role": { "label": "Income And Expenses Not Involving Cash Flows [Abstract]", "verboseLabel": "Income and expenses not involving cash flows:" } } }, "auth_ref": [] }, "ifrs-full_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "label": "Profit or loss [abstract]" } } }, "auth_ref": [] }, "ifrs-full_IncreaseDecreaseInCashAndCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IncreaseDecreaseInCashAndCashEquivalents", "crdr": "debit", "calculation": { "http://biolinerx.com/role/CondensedConsolidatedInterimCashFlowStatements": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://biolinerx.com/role/CondensedConsolidatedInterimCashFlowStatements" ], "lang": { "en-us": { "role": { "label": "Increase (decrease) in cash and cash equivalents after effect of exchange rate changes", "totalLabel": "INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS" } }, "en": { "role": { "documentation": "The increase (decrease) in cash and cash equivalents after the effect of exchange rate changes on cash and cash equivalents held in foreign currencies. [Refer: Cash and cash equivalents; Effect of exchange rate changes on cash and cash equivalents]" } } }, "auth_ref": [ "r24", "r80" ] }, "blrx_IncreaseDecreaseThoughPreFundedWarrantsExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://biolinerx.com/20260630", "localname": "IncreaseDecreaseThoughPreFundedWarrantsExercised", "crdr": "credit", "presentation": [ "http://biolinerx.com/role/CondensedInterimStatementsOfChangesInEquity" ], "lang": { "en-us": { "role": { "label": "Increase Decrease Though Pre Funded Warrants Exercised", "documentation": "The increase (decrease) through in equity resulting from the pre funded warrants exercised.", "verboseLabel": "Pre-funded warrants exercised" } } }, "auth_ref": [] }, "blrx_IncreaseDecreaseThroughExerciseOfPrefundedWarrantsShares": { "xbrltype": "sharesItemType", "nsuri": "http://biolinerx.com/20260630", "localname": "IncreaseDecreaseThroughExerciseOfPrefundedWarrantsShares", "presentation": [ "http://biolinerx.com/role/CondensedInterimStatementsOfChangesInEquity" ], "lang": { "en-us": { "role": { "label": "Increase (Decrease) Through Exercise Of Pre-funded Warrants Shares", "documentation": "Represents the increase (decrease) in equity resulting from the exercise of pre-funded warrants, shares.", "terseLabel": "Pre-funded warrants exercised, shares" } } }, "auth_ref": [] }, "blrx_IncreaseDecreaseThroughExpiredOfOptions": { "xbrltype": "monetaryItemType", "nsuri": "http://biolinerx.com/20260630", "localname": "IncreaseDecreaseThroughExpiredOfOptions", "crdr": "credit", "presentation": [ "http://biolinerx.com/role/CondensedInterimStatementsOfChangesInEquity" ], "lang": { "en-us": { "role": { "documentation": "The increase (decrease) in equity resulting from the expiration of options.", "label": "Increase Decrease Through Expired Of Options", "verboseLabel": "Employee stock options expired" } } }, "auth_ref": [] }, "ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IncreaseDecreaseThroughSharebasedPaymentTransactions", "crdr": "credit", "presentation": [ "http://biolinerx.com/role/CondensedInterimStatementsOfChangesInEquity" ], "lang": { "en-us": { "role": { "label": "Share-based compensation" } }, "en": { "role": { "documentation": "The increase (decrease) in equity resulting from share-based payment transactions. [Refer: Equity]" } } }, "auth_ref": [ "r115" ] }, "blrx_IncrementalInvestment": { "xbrltype": "monetaryItemType", "nsuri": "http://biolinerx.com/20260630", "localname": "IncrementalInvestment", "crdr": "debit", "presentation": [ "http://biolinerx.com/role/AGREEMENTWITHHEMISPHERIANFORDEVELOPMENTOFGLIX1NarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents amount of incremental investment.", "label": "Incremental Investment", "terseLabel": "Incremental investment" } } }, "auth_ref": [] }, "ecd_IndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "IndividualAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Individual [Axis]", "terseLabel": "Individual:" } } }, "auth_ref": [ "r168", "r178", "r188", "r211", "r219", "r223", "r231" ] }, "ecd_InsiderTradingArrLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "InsiderTradingArrLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Arrangements [Line Items]", "terseLabel": "Insider Trading Arrangements:" } } }, "auth_ref": [ "r229" ] }, "ecd_InsiderTradingPoliciesProcLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "InsiderTradingPoliciesProcLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures [Line Items]", "terseLabel": "Insider Trading Policies and Procedures:" } } }, "auth_ref": [ "r160", "r235" ] }, "ecd_InsiderTrdPoliciesProcAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "InsiderTrdPoliciesProcAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures Adopted [Flag]", "terseLabel": "Insider Trading Policies and Procedures Adopted" } } }, "auth_ref": [ "r160", "r235" ] }, "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]", "terseLabel": "Insider Trading Policies and Procedures Not Adopted" } } }, "auth_ref": [ "r160", "r235" ] }, "ifrs-full_IntangibleAssetsOtherThanGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IntangibleAssetsOtherThanGoodwill", "crdr": "debit", "calculation": { "http://biolinerx.com/role/CondensedConsolidatedInterimStatementsOfFinancialPosition": { "parentTag": "ifrs-full_NoncurrentAssets", "weight": 1.0, "order": 20.0 } }, "presentation": [ "http://biolinerx.com/role/CondensedConsolidatedInterimStatementsOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Intangible assets, net" } }, "en": { "role": { "documentation": "The amount of identifiable non-monetary assets without physical substance. This amount does not include goodwill. [Refer: Goodwill]" } } }, "auth_ref": [ "r14", "r90", "r121" ] }, "blrx_InterestAndExchangeDifferencesOnShortTermDeposits": { "xbrltype": "monetaryItemType", "nsuri": "http://biolinerx.com/20260630", "localname": "InterestAndExchangeDifferencesOnShortTermDeposits", "crdr": "debit", "calculation": { "http://biolinerx.com/role/CondensedConsolidatedInterimCashFlowStatements": { "parentTag": "blrx_TotalIncomeAndExpenseNotInvolvingCashFlows", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://biolinerx.com/role/CondensedConsolidatedInterimCashFlowStatements" ], "lang": { "en-us": { "role": { "documentation": "Interest and exchange differences on short-term deposits.", "label": "Interest And Exchange Differences On Short Term Deposits", "terseLabel": "Interest and exchange differences on short-term deposits", "verboseLabel": "Interest and exchange differences on short-term deposits" } } }, "auth_ref": [] }, "ifrs-full_Inventories": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "Inventories", "crdr": "debit", "calculation": { "http://biolinerx.com/role/CondensedConsolidatedInterimStatementsOfFinancialPosition": { "parentTag": "ifrs-full_CurrentAssets", "weight": 1.0, "order": 40.0 } }, "presentation": [ "http://biolinerx.com/role/CondensedConsolidatedInterimStatementsOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Current inventories", "verboseLabel": "Inventory" } }, "en": { "role": { "documentation": "The amount of current inventories. [Refer: Inventories]" } } }, "auth_ref": [ "r3", "r79", "r122", "r154" ] }, "ifrs-full_InvestmentProperty": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "InvestmentProperty", "crdr": "debit", "presentation": [ "http://biolinerx.com/role/AGREEMENTWITHHEMISPHERIANFORDEVELOPMENTOFGLIX1NarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Investment property", "terseLabel": "Investment" } }, "en": { "role": { "documentation": "The amount of property (land or a building - or part of a building - or both) held (by the owner or by the lessee as a right-of-use asset) to earn rentals or for capital appreciation or both, rather than for: (a) use in the production or supply of goods or services or for administrative purposes; or (b) sale in the ordinary course of business." } } }, "auth_ref": [ "r17", "r18", "r92", "r93", "r120" ] }, "blrx_IsraelNewShekelsMember": { "xbrltype": "domainItemType", "nsuri": "http://biolinerx.com/20260630", "localname": "IsraelNewShekelsMember", "presentation": [ "http://biolinerx.com/role/ShareholdersEquityScheduleOfShareCapitalDetails" ], "lang": { "en-us": { "role": { "documentation": "NIS [Member]", "label": "Israel New Shekels [Member]", "verboseLabel": "NIS [Member]" } } }, "auth_ref": [] }, "blrx_IssuanceCostOfWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://biolinerx.com/20260630", "localname": "IssuanceCostOfWarrants", "crdr": "debit", "calculation": { "http://biolinerx.com/role/CondensedConsolidatedInterimCashFlowStatements": { "parentTag": "blrx_TotalIncomeAndExpenseNotInvolvingCashFlows", "weight": 1.0, "order": 20.0 } }, "presentation": [ "http://biolinerx.com/role/CondensedConsolidatedInterimCashFlowStatements" ], "lang": { "en-us": { "role": { "label": "Issuance Cost Of Warrants", "documentation": "Represent the amount of Issuance cost of warrants", "verboseLabel": "Warrant issuance costs" } } }, "auth_ref": [] }, "blrx_IssuanceOfShareCapital": { "xbrltype": "monetaryItemType", "nsuri": "http://biolinerx.com/20260630", "localname": "IssuanceOfShareCapital", "crdr": "credit", "presentation": [ "http://biolinerx.com/role/CondensedInterimStatementsOfChangesInEquity" ], "lang": { "en-us": { "role": { "label": "Issuance Of Share Capital", "documentation": "This represents the issuance of share capital.", "terseLabel": "Issuance of share capital" } } }, "auth_ref": [] }, "blrx_IssuanceOfShareCapitalPreFundedWarrantsAndWarrantsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://biolinerx.com/20260630", "localname": "IssuanceOfShareCapitalPreFundedWarrantsAndWarrantsNet", "crdr": "credit", "presentation": [ "http://biolinerx.com/role/CondensedInterimStatementsOfChangesInEquity" ], "lang": { "en-us": { "role": { "label": "Issuance Of Share Capital Pre Funded Warrants And Warrants Net", "documentation": "Represents the value of share capital, pre-funded warrants and warrants issued.", "verboseLabel": "Issuance of share capital, pre-funded warrants and warrants, net" } } }, "auth_ref": [] }, "blrx_IssuanceOfShareCapitalPreFundedWarrantsAndWarrantsNetShares": { "xbrltype": "sharesItemType", "nsuri": "http://biolinerx.com/20260630", "localname": "IssuanceOfShareCapitalPreFundedWarrantsAndWarrantsNetShares", "presentation": [ "http://biolinerx.com/role/CondensedInterimStatementsOfChangesInEquity" ], "lang": { "en-us": { "role": { "label": "Issuance Of Share Capital Pre Funded Warrants And Warrants Net, Shares", "documentation": "It represents the share value of issuance of share capital pre funded warrants and warrants net, shares.", "terseLabel": "Issuance of share capital, pre-funded warrants and warrants, net, shares" } } }, "auth_ref": [] }, "blrx_IssuancesOfWarrantsMeasured": { "xbrltype": "monetaryItemType", "nsuri": "http://biolinerx.com/20260630", "localname": "IssuancesOfWarrantsMeasured", "crdr": "credit", "presentation": [ "http://biolinerx.com/role/FAIRVALUEMEASUREMENTOFWARRANTSUSINGSIGNIFICANTUNOBSERVABLEINPUTSLEVEL3Details" ], "lang": { "en-us": { "role": { "label": "Issuances Of Warrants Measured", "documentation": "Value of warrants issued during the period.", "terseLabel": "Issuances" } } }, "auth_ref": [] }, "blrx_IssuedAndPaidUpShareCapitalValue": { "xbrltype": "monetaryItemType", "nsuri": "http://biolinerx.com/20260630", "localname": "IssuedAndPaidUpShareCapitalValue", "crdr": "credit", "presentation": [ "http://biolinerx.com/role/ShareholdersEquityScheduleOfShareCapitalDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of issued and paid up share capital.", "label": "Issued And Paid Up Share Capital Value", "verboseLabel": "Issued and paid-up share capital" } } }, "auth_ref": [] }, "ifrs-full_IssuedCapital": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IssuedCapital", "crdr": "credit", "calculation": { "http://biolinerx.com/role/CondensedConsolidatedInterimStatementsOfFinancialPosition": { "parentTag": "ifrs-full_EquityAttributableToOwnersOfParent", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://biolinerx.com/role/CondensedConsolidatedInterimStatementsOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Ordinary shares" } }, "en": { "role": { "documentation": "The nominal value of capital issued." } } }, "auth_ref": [ "r150", "r157" ] }, "ifrs-full_IssuedCapitalMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IssuedCapitalMember", "presentation": [ "http://biolinerx.com/role/CondensedInterimStatementsOfChangesInEquity" ], "lang": { "en-us": { "role": { "label": "Ordinary shares [Member]" } }, "en": { "role": { "documentation": "This member stands for a component of equity representing issued capital." } } }, "auth_ref": [ "r116" ] }, "blrx_January2025OfferingMember": { "xbrltype": "domainItemType", "nsuri": "http://biolinerx.com/20260630", "localname": "January2025OfferingMember", "presentation": [ "http://biolinerx.com/role/EQUITYFINANCINGNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "January 2025 Offering [Member]", "documentation": "January 2025 Offering [Member]" } } }, "auth_ref": [] }, "ifrs-full_KeyManagementPersonnelCompensation": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "KeyManagementPersonnelCompensation", "crdr": "debit", "presentation": [ "http://biolinerx.com/role/EQUITYFINANCINGNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Compensation cost", "totalLabel": "Benefits to key executive personnel" } } }, "auth_ref": [ "r4", "r84" ] }, "ifrs-full_Level3OfFairValueHierarchyMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "Level3OfFairValueHierarchyMember", "presentation": [ "http://biolinerx.com/role/FAIRVALUEMEASUREMENTOFWARRANTSUSINGSIGNIFICANTUNOBSERVABLEINPUTSLEVEL3Details" ], "lang": { "en-us": { "role": { "label": "Level 3 of fair value hierarchy [member]", "terseLabel": "Level 3 [Member]" } }, "en": { "role": { "documentation": "This member stands for a category of the fair value hierarchy where inputs to the valuation techniques are unobservable inputs for the asset or liability. Unobservable inputs are inputs for which market data are not available and that are developed using the best information available about the assumptions that the market participants would use when pricing the asset or liability." } } }, "auth_ref": [ "r11", "r12", "r42", "r88", "r103" ] }, "ifrs-full_LevelsOfFairValueHierarchyAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "LevelsOfFairValueHierarchyAxis", "presentation": [ "http://biolinerx.com/role/FAIRVALUEMEASUREMENTOFWARRANTSUSINGSIGNIFICANTUNOBSERVABLEINPUTSLEVEL3Details" ], "lang": { "en-us": { "role": { "label": "Levels of fair value hierarchy [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r2", "r42", "r103" ] }, "ifrs-full_LevelsOfFairValueHierarchyDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "LevelsOfFairValueHierarchyDomain", "presentation": [ "http://biolinerx.com/role/FAIRVALUEMEASUREMENTOFWARRANTSUSINGSIGNIFICANTUNOBSERVABLEINPUTSLEVEL3Details" ], "lang": { "en-us": { "role": { "label": "Levels of fair value hierarchy [domain]" } }, "en": { "role": { "documentation": "This member stands for all levels of the fair value hierarchy. It also represents the standard value for the 'Levels of fair value hierarchy' axis if no other member is used." } } }, "auth_ref": [ "r2", "r42", "r103" ] }, "ifrs-full_Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "Liabilities", "crdr": "credit", "calculation": { "http://biolinerx.com/role/CondensedConsolidatedInterimStatementsOfFinancialPosition": { "parentTag": "ifrs-full_EquityAndLiabilities", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://biolinerx.com/role/CondensedConsolidatedInterimStatementsOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Liabilities", "totalLabel": "Total liabilities" } }, "en": { "role": { "documentation": "The amount of a present obligation of the entity to transfer an economic resource as a result of past events. Economic resource is a right that has the potential to produce economic benefits." } } }, "auth_ref": [ "r41", "r42", "r44", "r64", "r68", "r102", "r103", "r126" ] }, "blrx_MaturitiesOfShortTermDeposits": { "xbrltype": "monetaryItemType", "nsuri": "http://biolinerx.com/20260630", "localname": "MaturitiesOfShortTermDeposits", "crdr": "credit", "calculation": { "http://biolinerx.com/role/CondensedConsolidatedInterimCashFlowStatements": { "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities", "weight": -1.0, "order": 10.0 } }, "presentation": [ "http://biolinerx.com/role/CondensedConsolidatedInterimCashFlowStatements" ], "lang": { "en-us": { "role": { "documentation": "Maturities of short-term deposits.", "negatedLabel": "Maturities of short-term deposits", "label": "Maturities Of Short Term Deposits" } } }, "auth_ref": [] }, "ecd_MeasureAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "MeasureAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Measure [Axis]", "terseLabel": "Measure:" } } }, "auth_ref": [ "r203" ] }, "ecd_MeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "MeasureName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Measure Name", "terseLabel": "Name" } } }, "auth_ref": [ "r203" ] }, "ifrs-full_MeasurementAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "MeasurementAxis", "presentation": [ "http://biolinerx.com/role/FAIRVALUEMEASUREMENTOFWARRANTSUSINGSIGNIFICANTUNOBSERVABLEINPUTSLEVEL3Details" ], "lang": { "en-us": { "role": { "label": "Measurement [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r16", "r19", "r41", "r94", "r102" ] }, "ifrs-full_MeasurementDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "MeasurementDomain", "presentation": [ "http://biolinerx.com/role/FAIRVALUEMEASUREMENTOFWARRANTSUSINGSIGNIFICANTUNOBSERVABLEINPUTSLEVEL3Details" ], "lang": { "en-us": { "role": { "label": "Measurement [domain]" } }, "en": { "role": { "documentation": "This member stands for all types of measurement. It also represents the standard value for the 'Measurement' axis if no other member is used." } } }, "auth_ref": [ "r16", "r19", "r41", "r94", "r102" ] }, "blrx_MiscellaneousOtherComprehensiveLossMember": { "xbrltype": "domainItemType", "nsuri": "http://biolinerx.com/20260630", "localname": "MiscellaneousOtherComprehensiveLossMember", "presentation": [ "http://biolinerx.com/role/CondensedInterimStatementsOfChangesInEquity" ], "lang": { "en-us": { "role": { "documentation": "Other comprehensive loss [Member]", "label": "Miscellaneous Other Comprehensive Loss [Member]", "verboseLabel": "Other comprehensive loss [Member]" } } }, "auth_ref": [] }, "ecd_MnpiDiscTimedForCompValFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "MnpiDiscTimedForCompValFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "MNPI Disclosure Timed for Compensation Value [Flag]", "terseLabel": "MNPI Disclosure Timed for Compensation Value" } } }, "auth_ref": [ "r222" ] }, "blrx_MonthlyAdvisoryFee": { "xbrltype": "monetaryItemType", "nsuri": "http://biolinerx.com/20260630", "localname": "MonthlyAdvisoryFee", "crdr": "debit", "presentation": [ "http://biolinerx.com/role/AGREEMENTWITHHEMISPHERIANFORDEVELOPMENTOFGLIX1NarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents amount of monthly advisory fee.", "label": "Monthly Advisory Fee", "terseLabel": "Monthly advisory fee" } } }, "auth_ref": [] }, "ecd_MtrlTermsOfTrdArrTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "MtrlTermsOfTrdArrTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Material Terms of Trading Arrangement [Text Block]", "terseLabel": "Material Terms of Trading Arrangement" } } }, "auth_ref": [ "r230" ] }, "ecd_NamedExecutiveOfficersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "NamedExecutiveOfficersFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Named Executive Officers, Footnote [Text Block]", "terseLabel": "Named Executive Officers, Footnote" } } }, "auth_ref": [ "r204" ] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "NetIncomeLoss", "crdr": "credit", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Net Income (Loss)", "terseLabel": "Net Income (Loss)" } } }, "auth_ref": [] }, "ecd_NonGaapMeasureDescriptionTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "NonGaapMeasureDescriptionTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-GAAP Measure Description [Text Block]", "terseLabel": "Non-GAAP Measure Description" } } }, "auth_ref": [ "r203" ] }, "ecd_NonNeosMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "NonNeosMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-NEOs [Member]", "terseLabel": "Non-NEOs" } } }, "auth_ref": [ "r168", "r178", "r188", "r211", "r219" ] }, "ecd_NonPeoNeoAvgCompActuallyPaidAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "NonPeoNeoAvgCompActuallyPaidAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-PEO NEO Average Compensation Actually Paid Amount", "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount" } } }, "auth_ref": [ "r194" ] }, "ecd_NonPeoNeoAvgTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "NonPeoNeoAvgTotalCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-PEO NEO Average Total Compensation Amount", "terseLabel": "Non-PEO NEO Average Total Compensation Amount" } } }, "auth_ref": [ "r193" ] }, "ecd_NonPeoNeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "NonPeoNeoMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-PEO NEO [Member]", "terseLabel": "Non-PEO NEO" } } }, "auth_ref": [ "r211" ] }, "ecd_NonRule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "NonRule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]", "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted" } } }, "auth_ref": [ "r230" ] }, "ecd_NonRule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "NonRule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]", "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated" } } }, "auth_ref": [ "r230" ] }, "ifrs-full_NonadjustingEventsAfterReportingPeriodAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NonadjustingEventsAfterReportingPeriodAxis", "presentation": [ "http://biolinerx.com/role/SUBSEQUENTEVENTNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Non-adjusting events after reporting period [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r0", "r82" ] }, "ifrs-full_NonadjustingEventsAfterReportingPeriodDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NonadjustingEventsAfterReportingPeriodDomain", "presentation": [ "http://biolinerx.com/role/SUBSEQUENTEVENTNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Non-adjusting events after reporting period [domain]" } }, "en": { "role": { "documentation": "This member stands for events that occur between the end of the reporting period and the date when the financial statements are authorised for issue and are indicative of conditions that arose after the reporting period. It also represents the standard value for the 'Non-adjusting events after reporting period' axis if no other member is used." } } }, "auth_ref": [ "r0", "r82" ] }, "ifrs-full_NoncontrollingInterests": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NoncontrollingInterests", "crdr": "credit", "calculation": { "http://biolinerx.com/role/CondensedConsolidatedInterimStatementsOfFinancialPosition": { "parentTag": "ifrs-full_Equity", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://biolinerx.com/role/CondensedConsolidatedInterimStatementsOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Non-controlling interests", "terseLabel": "Non-controlling interest" } }, "en": { "role": { "documentation": "The amount of equity in a subsidiary not attributable, directly or indirectly, to a parent. [Refer: Total for all subsidiaries [member]]" } } }, "auth_ref": [ "r30", "r31", "r124" ] }, "ifrs-full_NoncontrollingInterestsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NoncontrollingInterestsMember", "presentation": [ "http://biolinerx.com/role/CondensedInterimStatementsOfChangesInEquity" ], "lang": { "en-us": { "role": { "label": "Non-controlling interests [member]", "verboseLabel": "Non-controlling interests [Member]" } }, "en": { "role": { "documentation": "This member stands for equity in a subsidiary not attributable, directly or indirectly, to the parent." } } }, "auth_ref": [ "r116" ] }, "ifrs-full_NoncurrentAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NoncurrentAssets", "crdr": "debit", "calculation": { "http://biolinerx.com/role/CondensedConsolidatedInterimStatementsOfFinancialPosition": { "parentTag": "ifrs-full_Assets", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://biolinerx.com/role/CondensedConsolidatedInterimStatementsOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Non-current assets", "totalLabel": "Total non-current assets" } }, "en": { "role": { "documentation": "The amount of assets that do not meet the definition of current assets. [Refer: Current assets]" } } }, "auth_ref": [ "r35", "r127", "r147" ] }, "ifrs-full_NoncurrentAssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NoncurrentAssetsAbstract", "presentation": [ "http://biolinerx.com/role/CondensedConsolidatedInterimStatementsOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "NON-CURRENT ASSETS" } } }, "auth_ref": [] }, "ifrs-full_NoncurrentLeaseLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NoncurrentLeaseLiabilities", "crdr": "credit", "calculation": { "http://biolinerx.com/role/CondensedConsolidatedInterimStatementsOfFinancialPosition": { "parentTag": "ifrs-full_NoncurrentLiabilities", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://biolinerx.com/role/CondensedConsolidatedInterimStatementsOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Non-current lease liabilities", "verboseLabel": "Lease liabilities" } }, "en": { "role": { "documentation": "The amount of non-current lease liabilities. [Refer: Lease liabilities]" } } }, "auth_ref": [ "r49" ] }, "ifrs-full_NoncurrentLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NoncurrentLiabilities", "crdr": "credit", "calculation": { "http://biolinerx.com/role/CondensedConsolidatedInterimStatementsOfFinancialPosition": { "parentTag": "ifrs-full_Liabilities", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://biolinerx.com/role/CondensedConsolidatedInterimStatementsOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Non-current liabilities", "totalLabel": "Total non-current liabilities" } }, "en": { "role": { "documentation": "The amount of liabilities that do not meet the definition of current liabilities. [Refer: Current liabilities]" } } }, "auth_ref": [ "r37", "r128", "r147" ] }, "ifrs-full_NoncurrentLiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NoncurrentLiabilitiesAbstract", "presentation": [ "http://biolinerx.com/role/CondensedConsolidatedInterimStatementsOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "NON-CURRENT LIABILITIES" } } }, "auth_ref": [] }, "ifrs-full_NoncurrentPortionOfNoncurrentLoansReceived": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NoncurrentPortionOfNoncurrentLoansReceived", "crdr": "credit", "calculation": { "http://biolinerx.com/role/CondensedConsolidatedInterimStatementsOfFinancialPosition": { "parentTag": "ifrs-full_NoncurrentLiabilities", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://biolinerx.com/role/CondensedConsolidatedInterimStatementsOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Long-term loans, net of current maturities", "terseLabel": "Long-term loan, net of current maturities" } }, "en": { "role": { "documentation": "The non-current portion of non-current loans received. [Refer: Loans received]" } } }, "auth_ref": [ "r250" ] }, "blrx_NumberOfAmericanDepositaryOrdinarySharesTraded": { "xbrltype": "sharesItemType", "nsuri": "http://biolinerx.com/20260630", "localname": "NumberOfAmericanDepositaryOrdinarySharesTraded", "presentation": [ "http://biolinerx.com/role/GENERALINFORMATIONNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Number Of American Depositary Ordinary Shares Traded", "documentation": "Represents the number of American depositary ordinary shares traded.", "verboseLabel": "Number of American depositary ordinary shares traded" } } }, "auth_ref": [] }, "blrx_NumberOfAmericanDepositarySharesIssuedToInvestors": { "xbrltype": "sharesItemType", "nsuri": "http://biolinerx.com/20260630", "localname": "NumberOfAmericanDepositarySharesIssuedToInvestors", "presentation": [ "http://biolinerx.com/role/SUBSEQUENTEVENTNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Number Of American Depositary Shares Issued To Investors", "documentation": "It represents number of American depositary shares issued to investors..", "verboseLabel": "Number of ADS issued to institutional investors" } } }, "auth_ref": [] }, "ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted": { "xbrltype": "decimalItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NumberOfInstrumentsOtherEquityInstrumentsGranted", "presentation": [ "http://biolinerx.com/role/SUBSEQUENTEVENTNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Number of other equity instruments granted in share-based payment arrangement", "verboseLabel": "Number of outstanding ordinary warrants to purchase" } }, "en": { "role": { "documentation": "The number of other equity instruments (ie other than share options) granted in a share-based payment arrangement." } } }, "auth_ref": [ "r56", "r247" ] }, "blrx_NumberOfNewSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://biolinerx.com/20260630", "localname": "NumberOfNewSharesIssued", "presentation": [ "http://biolinerx.com/role/CondensedInterimStatementsOfChangesInEquity" ], "lang": { "en-us": { "role": { "label": "Number Of New Shares Issued", "documentation": "The number of new shares issued by the entity.", "terseLabel": "Issuance of share capital , shares" } } }, "auth_ref": [] }, "blrx_NumberOfOrdinarySharesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://biolinerx.com/20260630", "localname": "NumberOfOrdinarySharesAbstract", "presentation": [ "http://biolinerx.com/role/ShareholdersEquityScheduleOfShareCapitalDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of ordinary shares.", "label": "Number Of Ordinary Shares [Abstract]", "verboseLabel": "Number of Ordinary Shares" } } }, "auth_ref": [] }, "ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement": { "xbrltype": "decimalItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement", "presentation": [ "http://biolinerx.com/role/EQUITYFINANCINGNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Number of other equity instruments exercisable in share-based payment arrangement", "terseLabel": "Number of other equity instruments exercisable" } }, "en": { "role": { "documentation": "The number of other equity instruments (ie other than share options) exercisable in a share-based payment arrangement." } } }, "auth_ref": [ "r247" ] }, "ifrs-full_NumberOfSharesAuthorised": { "xbrltype": "sharesItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NumberOfSharesAuthorised", "presentation": [ "http://biolinerx.com/role/ShareholdersEquityScheduleOfShareCapitalDetails" ], "lang": { "en-us": { "role": { "label": "Number Of Shares Authorised", "verboseLabel": "Authorized share capital (Shares)" } }, "en": { "role": { "documentation": "The number of shares authorised." } } }, "auth_ref": [ "r74", "r105", "r130" ] }, "ifrs-full_NumberOfSharesIssuedAndFullyPaid": { "xbrltype": "sharesItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NumberOfSharesIssuedAndFullyPaid", "presentation": [ "http://biolinerx.com/role/ShareholdersEquityScheduleOfShareCapitalDetails" ], "lang": { "en-us": { "role": { "label": "Number Of Shares Issued And Fully Paid", "verboseLabel": "Issued and paid-up share capital (Shares)" } }, "en": { "role": { "documentation": "The number of shares issued by the entity, for which full payment has been received." } } }, "auth_ref": [ "r75", "r106", "r131" ] }, "ifrs-full_NumberOfSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NumberOfSharesOutstanding", "presentation": [ "http://biolinerx.com/role/CondensedInterimStatementsOfChangesInEquity" ], "lang": { "en-us": { "role": { "label": "Number of shares outstanding", "periodEndLabel": "BALANCE, shares", "periodStartLabel": "BALANCE, shares" } }, "en": { "role": { "documentation": "The number of shares that have been authorised and issued, reduced by treasury shares held. [Refer: Treasury shares]" } } }, "auth_ref": [ "r76", "r107", "r132" ] }, "ifrs-full_OtherCurrentPayables": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "OtherCurrentPayables", "crdr": "credit", "calculation": { "http://biolinerx.com/role/CondensedConsolidatedInterimStatementsOfFinancialPosition": { "parentTag": "ifrs-full_CurrentLiabilities", "weight": 1.0, "order": 50.0 } }, "presentation": [ "http://biolinerx.com/role/CondensedConsolidatedInterimStatementsOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Other" } }, "en": { "role": { "documentation": "The amount of current payables that the entity does not separately disclose in the same statement or note." } } }, "auth_ref": [ "r251" ] }, "ifrs-full_OtherCurrentReceivables": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "OtherCurrentReceivables", "crdr": "debit", "calculation": { "http://biolinerx.com/role/CondensedConsolidatedInterimStatementsOfFinancialPosition": { "parentTag": "ifrs-full_CurrentAssets", "weight": 1.0, "order": 30.0 } }, "presentation": [ "http://biolinerx.com/role/CondensedConsolidatedInterimStatementsOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Other receivables" } }, "en": { "role": { "documentation": "The amount of current other receivables. [Refer: Other receivables]" } } }, "auth_ref": [ "r149", "r156" ] }, "ecd_OtherPerfMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "OtherPerfMeasureAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Other Performance Measure, Amount", "terseLabel": "Other Performance Measure, Amount" } } }, "auth_ref": [ "r203" ] }, "ecd_OutstandingAggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "OutstandingAggtErrCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Outstanding Aggregate Erroneous Compensation Amount", "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount" } } }, "auth_ref": [ "r166", "r176", "r186", "r217" ] }, "ecd_OutstandingRecoveryCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "OutstandingRecoveryCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Outstanding Recovery Compensation Amount", "terseLabel": "Compensation Amount" } } }, "auth_ref": [ "r169", "r179", "r189", "r220" ] }, "ecd_OutstandingRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "OutstandingRecoveryIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Outstanding Recovery, Individual Name", "terseLabel": "Name" } } }, "auth_ref": [ "r169", "r179", "r189", "r220" ] }, "ecd_PayVsPerformanceDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "PayVsPerformanceDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Line Items]", "terseLabel": "Pay vs Performance Disclosure" } } }, "auth_ref": [ "r192" ] }, "ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities", "crdr": "credit", "calculation": { "http://biolinerx.com/role/CondensedConsolidatedInterimCashFlowStatements": { "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": -1.0, "order": 20.0 } }, "presentation": [ "http://biolinerx.com/role/CondensedConsolidatedInterimCashFlowStatements" ], "lang": { "en-us": { "role": { "negatedLabel": "Repayments of lease liabilities", "label": "Payments of lease liabilities, classified as financing activities" } }, "en": { "role": { "documentation": "The cash outflow for payment of lease liabilities, classified as financing activities. [Refer: Lease liabilities]" } } }, "auth_ref": [ "r145" ] }, "ecd_PeerGroupIssuersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "PeerGroupIssuersFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Peer Group Issuers, Footnote [Text Block]", "terseLabel": "Peer Group Issuers, Footnote" } } }, "auth_ref": [ "r202" ] }, "ecd_PeerGroupTotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "PeerGroupTotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Peer Group Total Shareholder Return Amount", "terseLabel": "Peer Group Total Shareholder Return Amount" } } }, "auth_ref": [ "r202" ] }, "ecd_PeoActuallyPaidCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "PeoActuallyPaidCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "PEO Actually Paid Compensation Amount", "terseLabel": "PEO Actually Paid Compensation Amount" } } }, "auth_ref": [ "r194" ] }, "ecd_PeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "PeoMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "PEO [Member]", "terseLabel": "PEO" } } }, "auth_ref": [ "r211" ] }, "ecd_PeoName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "PeoName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "PEO Name", "terseLabel": "PEO Name" } } }, "auth_ref": [ "r204" ] }, "ecd_PeoTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "PeoTotalCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "PEO Total Compensation Amount", "terseLabel": "PEO Total Compensation Amount" } } }, "auth_ref": [ "r193" ] }, "blrx_PercentageOfAdditionalEquityInterest": { "xbrltype": "percentItemType", "nsuri": "http://biolinerx.com/20260630", "localname": "PercentageOfAdditionalEquityInterest", "presentation": [ "http://biolinerx.com/role/AGREEMENTWITHHEMISPHERIANFORDEVELOPMENTOFGLIX1NarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents percentage of additional equity interest.", "label": "Percentage Of Additional Equity Interest", "terseLabel": "Percentage of additional equity interest" } } }, "auth_ref": [] }, "blrx_PercentageOfCommissionOnSalesAgreement": { "xbrltype": "percentItemType", "nsuri": "http://biolinerx.com/20260630", "localname": "PercentageOfCommissionOnSalesAgreement", "presentation": [ "http://biolinerx.com/role/At-the-marketAtmSalesAgreementWithBtigDetails" ], "lang": { "en-us": { "role": { "documentation": "Percentage of commission on sales agreement.", "label": "Percentage of commission on sales agreement" } } }, "auth_ref": [] }, "blrx_PercentageOfIssuedShareCapitalReceived": { "xbrltype": "percentItemType", "nsuri": "http://biolinerx.com/20260630", "localname": "PercentageOfIssuedShareCapitalReceived", "presentation": [ "http://biolinerx.com/role/AGREEMENTWITHHEMISPHERIANFORDEVELOPMENTOFGLIX1NarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents percentage of issued share capital received.", "label": "Percentage Of Issued Share Capital Received", "terseLabel": "Percentage of issued share capital received" } } }, "auth_ref": [] }, "blrx_PercentageOfIssuedShareCapitalReceivedWithinMonths": { "xbrltype": "percentItemType", "nsuri": "http://biolinerx.com/20260630", "localname": "PercentageOfIssuedShareCapitalReceivedWithinMonths", "presentation": [ "http://biolinerx.com/role/AGREEMENTWITHHEMISPHERIANFORDEVELOPMENTOFGLIX1NarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents percentage of issued share capital.", "label": "Percentage Of Issued Share Capital Received Within Months", "terseLabel": "Percentage of issued share capital received within 36 months" } } }, "auth_ref": [] }, "blrx_PercentageOfOwnershipStake": { "xbrltype": "percentItemType", "nsuri": "http://biolinerx.com/20260630", "localname": "PercentageOfOwnershipStake", "presentation": [ "http://biolinerx.com/role/AGREEMENTWITHHEMISPHERIANFORDEVELOPMENTOFGLIX1NarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Perpresents percentage of ownership.", "label": "Percentage Of Ownership Stake", "terseLabel": "Percentage of ownership stake" } } }, "auth_ref": [] }, "blrx_PlacementAgentMember": { "xbrltype": "domainItemType", "nsuri": "http://biolinerx.com/20260630", "localname": "PlacementAgentMember", "presentation": [ "http://biolinerx.com/role/EQUITYFINANCINGNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Placement Agent [Member]", "documentation": "placement agent [Member]" } } }, "auth_ref": [] }, "ecd_PnsnAdjsPrrSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "PnsnAdjsPrrSvcCstMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Pension Adjustments Prior Service Cost [Member]", "terseLabel": "Pension Adjustments Prior Service Cost" } } }, "auth_ref": [ "r195" ] }, "ecd_PnsnAdjsSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "PnsnAdjsSvcCstMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Pension Adjustments Service Cost [Member]", "terseLabel": "Pension Adjustments Service Cost" } } }, "auth_ref": [ "r239" ] }, "ecd_PnsnBnftsAdjFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "PnsnBnftsAdjFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Pension Benefits Adjustments, Footnote [Text Block]", "terseLabel": "Pension Benefits Adjustments, Footnote" } } }, "auth_ref": [ "r194" ] }, "blrx_PreFundedWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://biolinerx.com/20260630", "localname": "PreFundedWarrantsMember", "presentation": [ "http://biolinerx.com/role/EQUITYFINANCINGNarrativeDetails", "http://biolinerx.com/role/SUBSEQUENTEVENTNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Pre Funded Warrants [Member]", "documentation": "Pre Funded Warrants [Member]", "verboseLabel": "Pre-funded warrants [Member]" } } }, "auth_ref": [] }, "ifrs-full_ProceedsFromExerciseOfWarrants": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ProceedsFromExerciseOfWarrants", "crdr": "debit", "presentation": [ "http://biolinerx.com/role/SUBSEQUENTEVENTNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Proceeds from exercise of warrants", "verboseLabel": "Proceeds from exercise of warrants" } }, "en": { "role": { "documentation": "The cash inflow from the exercise of share purchase warrants." } } }, "auth_ref": [ "r242" ] }, "blrx_ProceedsFromExerciseOfWarrantsAfterDeductingFeesAndExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://biolinerx.com/20260630", "localname": "ProceedsFromExerciseOfWarrantsAfterDeductingFeesAndExpenses", "crdr": "debit", "presentation": [ "http://biolinerx.com/role/EQUITYFINANCINGNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Proceeds From Exercise Of Warrants After Deducting Fees And Expenses", "documentation": "Proceeds from exercise of warrants after deducting fees and expenses.", "terseLabel": "Proceeds from exercise of warrants after deducting fees and expenses" } } }, "auth_ref": [] }, "blrx_ProceedsFromExerciseWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://biolinerx.com/20260630", "localname": "ProceedsFromExerciseWarrants", "crdr": "debit", "presentation": [ "http://biolinerx.com/role/EQUITYFINANCINGNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Proceeds From Exercise Warrants", "documentation": "The cash inflow from the exercise share purchase warrants.", "terseLabel": "Proceeds from exercise of warrants" } } }, "auth_ref": [] }, "ifrs-full_ProceedsFromIssueOfOrdinaryShares": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ProceedsFromIssueOfOrdinaryShares", "crdr": "debit", "presentation": [ "http://biolinerx.com/role/EQUITYFINANCINGNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Net proceeds from transaction" } }, "en": { "role": { "documentation": "The cash inflow from the issuing of ordinary shares. [Refer: Ordinary shares [member]]" } } }, "auth_ref": [ "r242" ] }, "ifrs-full_ProceedsFromIssuingShares": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ProceedsFromIssuingShares", "crdr": "debit", "calculation": { "http://biolinerx.com/role/CondensedConsolidatedInterimCashFlowStatements": { "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://biolinerx.com/role/CondensedConsolidatedInterimCashFlowStatements" ], "lang": { "en-us": { "role": { "label": "Issuance of share capital and warrants, net of issuance cost", "verboseLabel": "Gross proceeds", "terseLabel": "Issuance of share capital and warrants, net of issuance costs" } }, "en": { "role": { "documentation": "The cash inflow from issuing shares." } } }, "auth_ref": [ "r144" ] }, "ifrs-full_ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities", "crdr": "debit", "calculation": { "http://biolinerx.com/role/CondensedConsolidatedInterimCashFlowStatements": { "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities", "weight": 1.0, "order": 20.0 } }, "presentation": [ "http://biolinerx.com/role/CondensedConsolidatedInterimCashFlowStatements" ], "lang": { "en-us": { "role": { "label": "Proceeds from sales of property, plant and equipment, classified as investing activities", "verboseLabel": "Proceeds from sale of property and equipment" } }, "en": { "role": { "documentation": "The cash inflow from sales of property, plant and equipment, classified as investing activities. [Refer: Property, plant and equipment]" } } }, "auth_ref": [ "r143" ] }, "blrx_ProceedsFromWarrantIssue": { "xbrltype": "monetaryItemType", "nsuri": "http://biolinerx.com/20260630", "localname": "ProceedsFromWarrantIssue", "crdr": "debit", "presentation": [ "http://biolinerx.com/role/EQUITYFINANCINGNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Proceeds from warrant issue.", "label": "Proceeds From Warrant Issue", "verboseLabel": "Proceeds from warrant issue", "terseLabel": "Proceeds from warrant issue, net" } } }, "auth_ref": [] }, "ifrs-full_ProfessionalFeesExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ProfessionalFeesExpense", "crdr": "debit", "presentation": [ "http://biolinerx.com/role/At-the-marketAtmSalesAgreementWithBtigDetails" ], "lang": { "en-us": { "role": { "label": "Professional fees expense", "terseLabel": "Total fees" } } }, "auth_ref": [ "r250" ] }, "ifrs-full_ProfitLoss": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ProfitLoss", "crdr": "credit", "calculation": { "http://biolinerx.com/role/CondensedConsolidatedInterimCashFlowStatements": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": 1.0, "order": 0.0 }, "http://biolinerx.com/role/CondensedConsolidatedInterimStatementsOfComprehensiveLoss": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://biolinerx.com/role/CondensedConsolidatedInterimCashFlowStatements", "http://biolinerx.com/role/CondensedConsolidatedInterimStatementsOfComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Profit (loss)", "terseLabel": "NET INCOME (LOSS) AND COMPREHENSIVE INCOME (LOSS)", "totalLabel": "NET INCOME (LOSS) AND COMPREHENSIVE INCOME (LOSS)", "verboseLabel": "Comprehensive income (loss) for the period" } }, "en": { "role": { "documentation": "The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]" } } }, "auth_ref": [ "r27", "r29", "r64", "r66", "r87", "r96", "r114", "r135", "r147", "r148" ] }, "ifrs-full_ProfitLossAttributableToAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ProfitLossAttributableToAbstract", "presentation": [ "http://biolinerx.com/role/CondensedConsolidatedInterimStatementsOfComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Profit (loss), attributable to [abstract]", "terseLabel": "ATTRIBUTION OF NET INCOME (LOSS) AND COMPREHENSIVE INCOME (LOSS)" } } }, "auth_ref": [] }, "blrx_ProfitLossFromNonOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://biolinerx.com/20260630", "localname": "ProfitLossFromNonOperatingActivities", "crdr": "credit", "calculation": { "http://biolinerx.com/role/CondensedConsolidatedInterimStatementsOfComprehensiveLoss": { "parentTag": "ifrs-full_ProfitLoss", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://biolinerx.com/role/CondensedConsolidatedInterimStatementsOfComprehensiveLoss" ], "lang": { "en-us": { "role": { "documentation": "Non operating profit (loss) from operating activities of the entity.", "label": "Profit Loss From Non Operating Activities", "terseLabel": "NON-OPERATING INCOME (EXPENSES), NET", "verboseLabel": "NON-OPERATING EXPENSES, NET" } } }, "auth_ref": [] }, "ifrs-full_ProfitLossFromOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ProfitLossFromOperatingActivities", "crdr": "credit", "calculation": { "http://biolinerx.com/role/CondensedConsolidatedInterimStatementsOfComprehensiveLoss": { "parentTag": "ifrs-full_ProfitLoss", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://biolinerx.com/role/CondensedConsolidatedInterimStatementsOfComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Profit (loss) from operating activities", "totalLabel": "OPERATING LOSS" } } }, "auth_ref": [ "r142", "r253" ] }, "ifrs-full_PropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "PropertyPlantAndEquipment", "crdr": "debit", "calculation": { "http://biolinerx.com/role/CondensedConsolidatedInterimStatementsOfFinancialPosition": { "parentTag": "ifrs-full_NoncurrentAssets", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://biolinerx.com/role/CondensedConsolidatedInterimStatementsOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Property and equipment, net" } }, "en": { "role": { "documentation": "The amount of tangible assets that: (a) are held for use in the production or supply of goods or services, for rental to others, or for administrative purposes; and (b) are expected to be used during more than one period. Note that right-of-use assets are not included. [Contrast: Property, plant and equipment including right-of-use assets]" } } }, "auth_ref": [ "r1", "r83", "r119" ] }, "ifrs-full_ProportionOfOwnershipInterestInAssociate": { "xbrltype": "percentItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ProportionOfOwnershipInterestInAssociate", "presentation": [ "http://biolinerx.com/role/AGREEMENTWITHHEMISPHERIANFORDEVELOPMENTOFGLIX1NarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Proportion of ownership interest in associate", "terseLabel": "Percentage of aggregate maximum ownership" } }, "en": { "role": { "documentation": "The proportion of ownership interest in an associate attributable to the entity. [Refer: Total for all associates [member]]" } } }, "auth_ref": [ "r6", "r7", "r32" ] }, "ecd_PvpTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "PvpTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Table]", "terseLabel": "Pay vs Performance Disclosure" } } }, "auth_ref": [ "r192" ] }, "ecd_PvpTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "PvpTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Pay vs Performance [Table Text Block]", "terseLabel": "Pay vs Performance Disclosure, Table" } } }, "auth_ref": [ "r192" ] }, "blrx_RecognitionOfDayOneLossWithinProfitOrLossWarrantsMeasured": { "xbrltype": "monetaryItemType", "nsuri": "http://biolinerx.com/20260630", "localname": "RecognitionOfDayOneLossWithinProfitOrLossWarrantsMeasured", "crdr": "credit", "presentation": [ "http://biolinerx.com/role/FAIRVALUEMEASUREMENTOFWARRANTSUSINGSIGNIFICANTUNOBSERVABLEINPUTSLEVEL3Details" ], "lang": { "en-us": { "role": { "label": "Recognition Of Day One Loss Within Profit Or Loss Warrants Measured", "documentation": "Amount of Day One loss recognized in profit or loss for warrants.", "terseLabel": "Recognition of Day One loss within profit or loss" } } }, "auth_ref": [] }, "ecd_RecoveryOfErrCompDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "RecoveryOfErrCompDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]", "terseLabel": "Recovery of Erroneously Awarded Compensation Disclosure" } } }, "auth_ref": [ "r161", "r171", "r181", "r212" ] }, "ifrs-full_RepaymentsOfCurrentBorrowings": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "RepaymentsOfCurrentBorrowings", "crdr": "credit", "calculation": { "http://biolinerx.com/role/CondensedConsolidatedInterimCashFlowStatements": { "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": -1.0, "order": 10.0 } }, "presentation": [ "http://biolinerx.com/role/CondensedConsolidatedInterimCashFlowStatements" ], "lang": { "en-us": { "role": { "negatedLabel": "Repayments of loan", "label": "Repayments of current borrowings" } }, "en": { "role": { "documentation": "The cash outflow for repayments of current borrowings. [Refer: Current borrowings]" } } }, "auth_ref": [ "r242" ] }, "ifrs-full_ResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ResearchAndDevelopmentExpense", "crdr": "debit", "calculation": { "http://biolinerx.com/role/CondensedConsolidatedInterimStatementsOfComprehensiveLoss": { "parentTag": "ifrs-full_ProfitLossFromOperatingActivities", "weight": -1.0, "order": 30.0 } }, "presentation": [ "http://biolinerx.com/role/CondensedConsolidatedInterimStatementsOfComprehensiveLoss" ], "lang": { "en-us": { "role": { "negatedLabel": "RESEARCH AND DEVELOPMENT EXPENSES", "label": "Research And Development Expense" } } }, "auth_ref": [ "r15", "r91" ] }, "ecd_RestatementDateAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "RestatementDateAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Restatement Determination Date [Axis]", "terseLabel": "Restatement Determination Date:" } } }, "auth_ref": [ "r162", "r172", "r182", "r213" ] }, "ecd_RestatementDeterminationDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "RestatementDeterminationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Restatement Determination Date", "terseLabel": "Restatement Determination Date" } } }, "auth_ref": [ "r163", "r173", "r183", "r214" ] }, "ecd_RestatementDoesNotRequireRecoveryTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "RestatementDoesNotRequireRecoveryTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Restatement Does Not Require Recovery [Text Block]", "terseLabel": "Restatement does not require Recovery" } } }, "auth_ref": [ "r170", "r180", "r190", "r221" ] }, "ifrs-full_RetainedEarnings": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "RetainedEarnings", "crdr": "credit", "calculation": { "http://biolinerx.com/role/CondensedConsolidatedInterimStatementsOfFinancialPosition": { "parentTag": "ifrs-full_EquityAttributableToOwnersOfParent", "weight": 1.0, "order": 50.0 } }, "presentation": [ "http://biolinerx.com/role/CondensedConsolidatedInterimStatementsOfFinancialPosition", "http://biolinerx.com/role/GENERALINFORMATIONNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Accumulated deficit", "verboseLabel": "Accumulated losses" } }, "en": { "role": { "documentation": "A component of equity representing the entity's cumulative undistributed earnings or deficit." } } }, "auth_ref": [ "r150", "r157", "r158" ] }, "ifrs-full_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "RetainedEarningsMember", "presentation": [ "http://biolinerx.com/role/CondensedInterimStatementsOfChangesInEquity" ], "lang": { "en-us": { "role": { "label": "Accumulated deficit [Member]" } }, "en": { "role": { "documentation": "This member stands for a component of equity representing an entity's cumulative undistributed earnings or deficit." } } }, "auth_ref": [ "r116", "r153" ] }, "ifrs-full_Revenue": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "Revenue", "crdr": "credit", "calculation": { "http://biolinerx.com/role/CondensedConsolidatedInterimStatementsOfComprehensiveLoss": { "parentTag": "ifrs-full_GrossProfit", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://biolinerx.com/role/CondensedConsolidatedInterimStatementsOfComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Revenue", "terseLabel": "ROYALTY REVENUES", "verboseLabel": "REVENUES", "totalLabel": "ROYALTY REVENUES" } } }, "auth_ref": [ "r39", "r57", "r63", "r65", "r69", "r70", "r71", "r139", "r147", "r151", "r152" ] }, "ifrs-full_RightofuseAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "RightofuseAssets", "crdr": "debit", "calculation": { "http://biolinerx.com/role/CondensedConsolidatedInterimStatementsOfFinancialPosition": { "parentTag": "ifrs-full_NoncurrentAssets", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://biolinerx.com/role/CondensedConsolidatedInterimStatementsOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Right-of-use assets, net" } }, "en": { "role": { "documentation": "The amount of assets that represent a lessee's right to use an underlying asset for the lease term that do not meet the definition of investment property. Underlying asset is an asset that is the subject of a lease, for which the right to use that asset has been provided by a lessor to a lessee." } } }, "auth_ref": [ "r48", "r50", "r72" ] }, "ecd_Rule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "Rule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Rule 10b5-1 Arrangement Adopted [Flag]", "terseLabel": "Rule 10b5-1 Arrangement Adopted" } } }, "auth_ref": [ "r230" ] }, "ecd_Rule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "Rule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Rule 10b5-1 Arrangement Terminated [Flag]", "terseLabel": "Rule 10b5-1 Arrangement Terminated" } } }, "auth_ref": [ "r230" ] }, "blrx_SaleOfStockNumberOfSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://biolinerx.com/20260630", "localname": "SaleOfStockNumberOfSharesIssued", "presentation": [ "http://biolinerx.com/role/At-the-marketAtmSalesAgreementWithBtigDetails" ], "lang": { "en-us": { "role": { "label": "Sale Of Stock Number Of Shares Issued", "documentation": "it represents sale of stock.", "verboseLabel": "Sale of stock" } } }, "auth_ref": [] }, "ifrs-full_SalesAndMarketingExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "SalesAndMarketingExpense", "crdr": "debit", "calculation": { "http://biolinerx.com/role/CondensedConsolidatedInterimStatementsOfComprehensiveLoss": { "parentTag": "ifrs-full_ProfitLossFromOperatingActivities", "weight": -1.0, "order": 10.0 } }, "presentation": [ "http://biolinerx.com/role/CondensedConsolidatedInterimStatementsOfComprehensiveLoss" ], "lang": { "en-us": { "role": { "negatedLabel": "SALES AND MARKETING EXPENSES", "label": "Sales And Marketing Expense" } } }, "auth_ref": [ "r253" ] }, "ifrs-full_SellingGeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "SellingGeneralAndAdministrativeExpense", "crdr": "debit", "calculation": { "http://biolinerx.com/role/CondensedConsolidatedInterimStatementsOfComprehensiveLoss": { "parentTag": "ifrs-full_ProfitLossFromOperatingActivities", "weight": -1.0, "order": 20.0 } }, "presentation": [ "http://biolinerx.com/role/CondensedConsolidatedInterimStatementsOfComprehensiveLoss" ], "lang": { "en-us": { "role": { "negatedLabel": "GENERAL AND ADMINISTRATIVE EXPENSES", "label": "Selling General And Administrative Expense" } } }, "auth_ref": [ "r253" ] }, "blrx_September2022OfferingMember": { "xbrltype": "domainItemType", "nsuri": "http://biolinerx.com/20260630", "localname": "September2022OfferingMember", "presentation": [ "http://biolinerx.com/role/EQUITYFINANCINGNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "September 2022 Offering [Member]", "documentation": "September 2022 offering." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "All Award Types", "terseLabel": "All Award Types" } } }, "auth_ref": [] }, "ifrs-full_SharePremium": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "SharePremium", "crdr": "credit", "calculation": { "http://biolinerx.com/role/CondensedConsolidatedInterimStatementsOfFinancialPosition": { "parentTag": "ifrs-full_EquityAttributableToOwnersOfParent", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://biolinerx.com/role/CondensedConsolidatedInterimStatementsOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Share premium" } }, "en": { "role": { "documentation": "The amount received or receivable from the issuance of the entity's shares in excess of nominal value." } } }, "auth_ref": [ "r150", "r157" ] }, "ifrs-full_SharePremiumMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "SharePremiumMember", "presentation": [ "http://biolinerx.com/role/CondensedInterimStatementsOfChangesInEquity" ], "lang": { "en-us": { "role": { "label": "Share premium [Member]" } }, "en": { "role": { "documentation": "This member stands for the amount received or receivable from issuance of the entity's shares in excess of nominal value." } } }, "auth_ref": [ "r116" ] }, "blrx_SharesIssuedRegisteredDirectOfferings": { "xbrltype": "sharesItemType", "nsuri": "http://biolinerx.com/20260630", "localname": "SharesIssuedRegisteredDirectOfferings", "presentation": [ "http://biolinerx.com/role/EQUITYFINANCINGNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Registered direct offerings sales.", "label": "Shares Issued Registered Direct Offerings", "verboseLabel": "Registered direct offerings sales", "terseLabel": "Registered direct offerings sales" } } }, "auth_ref": [] }, "ifrs-full_ShorttermInvestmentsClassifiedAsCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ShorttermInvestmentsClassifiedAsCashEquivalents", "crdr": "debit", "calculation": { "http://biolinerx.com/role/CondensedConsolidatedInterimStatementsOfFinancialPosition": { "parentTag": "ifrs-full_CurrentAssets", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://biolinerx.com/role/CondensedConsolidatedInterimStatementsOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Short-term bank deposits" } }, "en": { "role": { "documentation": "A classification of cash equivalents representing short-term investments. [Refer: Cash equivalents]" } } }, "auth_ref": [ "r246" ] }, "ifrs-full_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "label": "Statement of cash flows [abstract]" } } }, "auth_ref": [] }, "ifrs-full_StatementOfChangesInEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "StatementOfChangesInEquityAbstract", "auth_ref": [] }, "ifrs-full_StatementOfChangesInEquityLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "StatementOfChangesInEquityLineItems", "presentation": [ "http://biolinerx.com/role/CondensedInterimStatementsOfChangesInEquity" ], "lang": { "en-us": { "role": { "label": "Statement of changes in equity [line items]" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_StatementOfChangesInEquityTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "StatementOfChangesInEquityTable", "presentation": [ "http://biolinerx.com/role/CondensedInterimStatementsOfChangesInEquity" ], "lang": { "en-us": { "role": { "label": "Statement of changes in equity [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to changes in equity." } } }, "auth_ref": [ "r116" ] }, "ifrs-full_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "label": "Statement of financial position [abstract]" } } }, "auth_ref": [] }, "ecd_StkPrcOrTsrEstimationMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "StkPrcOrTsrEstimationMethodTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Stock Price or TSR Estimation Method [Text Block]", "terseLabel": "Stock Price or TSR Estimation Method" } } }, "auth_ref": [ "r165", "r175", "r185", "r216" ] }, "us-gaap_StockAppreciationRightsSARSMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "StockAppreciationRightsSARSMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Stock Appreciation Rights (SARs) [Member]", "terseLabel": "Stock Appreciation Rights (SARs)" } } }, "auth_ref": [] }, "blrx_SupplementalInformationOnInterestPaidInCash": { "xbrltype": "monetaryItemType", "nsuri": "http://biolinerx.com/20260630", "localname": "SupplementalInformationOnInterestPaidInCash", "crdr": "debit", "presentation": [ "http://biolinerx.com/role/CondensedConsolidatedInterimCashFlowStatements" ], "lang": { "en-us": { "role": { "documentation": "Supplemental information on interest paid in cash.", "label": "Supplemental information on interest paid in cash" } } }, "auth_ref": [] }, "blrx_SupplementalInformationOnInterestReceivedInCash": { "xbrltype": "monetaryItemType", "nsuri": "http://biolinerx.com/20260630", "localname": "SupplementalInformationOnInterestReceivedInCash", "crdr": "debit", "presentation": [ "http://biolinerx.com/role/CondensedConsolidatedInterimCashFlowStatements" ], "lang": { "en-us": { "role": { "documentation": "Supplemental information on interest received in cash.", "label": "Supplemental information on interest received in cash" } } }, "auth_ref": [] }, "blrx_SupplementalInformationOnNonCashTransactionsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://biolinerx.com/20260630", "localname": "SupplementalInformationOnNonCashTransactionsAbstract", "presentation": [ "http://biolinerx.com/role/CondensedConsolidatedInterimCashFlowStatements" ], "lang": { "en-us": { "role": { "label": "Supplemental Information On Non Cash Transactions [Abstract]", "verboseLabel": "Supplemental information on non-cash transactions:" } } }, "auth_ref": [] }, "ecd_TabularListTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "TabularListTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Tabular List [Table Text Block]", "terseLabel": "Tabular List, Table" } } }, "auth_ref": [ "r210" ] }, "blrx_TetragonMember": { "xbrltype": "domainItemType", "nsuri": "http://biolinerx.com/20260630", "localname": "TetragonMember", "presentation": [ "http://biolinerx.com/role/AGREEMENTWITHHEMISPHERIANFORDEVELOPMENTOFGLIX1NarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Tetragon [Member]" } } }, "auth_ref": [] }, "blrx_TotalChangeInOperatingAssetAndLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://biolinerx.com/20260630", "localname": "TotalChangeInOperatingAssetAndLiability", "crdr": "debit", "calculation": { "http://biolinerx.com/role/CondensedConsolidatedInterimCashFlowStatements": { "parentTag": "ifrs-full_AdjustmentsForReconcileProfitLoss", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://biolinerx.com/role/CondensedConsolidatedInterimCashFlowStatements" ], "lang": { "en-us": { "role": { "documentation": "Total Change in operating asset and liability.", "label": "Total Change In Operating Asset And Liability", "totalLabel": "Total Change in operating asset and liability" } } }, "auth_ref": [] }, "blrx_TotalIncomeAndExpenseNotInvolvingCashFlows": { "xbrltype": "monetaryItemType", "nsuri": "http://biolinerx.com/20260630", "localname": "TotalIncomeAndExpenseNotInvolvingCashFlows", "crdr": "debit", "calculation": { "http://biolinerx.com/role/CondensedConsolidatedInterimCashFlowStatements": { "parentTag": "ifrs-full_AdjustmentsForReconcileProfitLoss", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://biolinerx.com/role/CondensedConsolidatedInterimCashFlowStatements" ], "lang": { "en-us": { "role": { "documentation": "Total income and expense not involving cash flows.", "label": "Total Income And Expense Not Involving Cash Flows", "totalLabel": "Total income and expense not involving cash flows" } } }, "auth_ref": [] }, "ecd_TotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "TotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Total Shareholder Return Amount", "terseLabel": "Total Shareholder Return Amount" } } }, "auth_ref": [ "r202" ] }, "ecd_TotalShareholderRtnVsPeerGroupTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "TotalShareholderRtnVsPeerGroupTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Total Shareholder Return Vs Peer Group [Text Block]", "terseLabel": "Total Shareholder Return Vs Peer Group" } } }, "auth_ref": [ "r209" ] }, "ifrs-full_TradeAndOtherCurrentPayablesAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "TradeAndOtherCurrentPayablesAbstract", "presentation": [ "http://biolinerx.com/role/CondensedConsolidatedInterimStatementsOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Accounts payable and accruals:" } } }, "auth_ref": [] }, "ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "TradeAndOtherCurrentPayablesToTradeSuppliers", "crdr": "credit", "calculation": { "http://biolinerx.com/role/CondensedConsolidatedInterimStatementsOfFinancialPosition": { "parentTag": "ifrs-full_CurrentLiabilities", "weight": 1.0, "order": 40.0 } }, "presentation": [ "http://biolinerx.com/role/CondensedConsolidatedInterimStatementsOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Trade" } }, "en": { "role": { "documentation": "The current amount of payment due to suppliers for goods and services used in entity's business. [Refer: Current liabilities; Trade payables]" } } }, "auth_ref": [ "r155", "r252" ] }, "ecd_TradingArrAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "TradingArrAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement [Axis]", "terseLabel": "Trading Arrangement:" } } }, "auth_ref": [ "r229" ] }, "ecd_TradingArrByIndTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "TradingArrByIndTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangements, by Individual [Table]", "terseLabel": "Trading Arrangements, by Individual" } } }, "auth_ref": [ "r231" ] }, "ecd_TrdArrAdoptionDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "TrdArrAdoptionDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement Adoption Date", "terseLabel": "Adoption Date" } } }, "auth_ref": [ "r232" ] }, "ecd_TrdArrDuration": { "xbrltype": "durationItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "TrdArrDuration", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement Duration", "terseLabel": "Arrangement Duration" } } }, "auth_ref": [ "r233" ] }, "ecd_TrdArrExpirationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "TrdArrExpirationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement Expiration Date", "terseLabel": "Expiration Date" } } }, "auth_ref": [ "r233" ] }, "ecd_TrdArrIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "TrdArrIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement, Individual Name", "terseLabel": "Name" } } }, "auth_ref": [ "r231" ] }, "ecd_TrdArrIndTitle": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "TrdArrIndTitle", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement, Individual Title", "terseLabel": "Title" } } }, "auth_ref": [ "r231" ] }, "ecd_TrdArrSecuritiesAggAvailAmt": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "TrdArrSecuritiesAggAvailAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement, Securities Aggregate Available Amount", "terseLabel": "Aggregate Available" } } }, "auth_ref": [ "r234" ] }, "ecd_TrdArrTerminationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "TrdArrTerminationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement Termination Date", "terseLabel": "Termination Date" } } }, "auth_ref": [ "r232" ] }, "ifrs-full_TypesOfInvestmentPropertyAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "TypesOfInvestmentPropertyAxis", "presentation": [ "http://biolinerx.com/role/EQUITYFINANCINGNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Types of investment property [axis]", "verboseLabel": "Types of investment property [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r250" ] }, "ifrs-full_TypesOfInvestmentPropertyDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "TypesOfInvestmentPropertyDomain", "presentation": [ "http://biolinerx.com/role/EQUITYFINANCINGNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Types of investment property [domain]" } }, "en": { "role": { "documentation": "This member stands for the standard value for the 'Types of investment property' axis if no other member is used." } } }, "auth_ref": [ "r250" ] }, "ecd_UndrlygSecurityMktPriceChngPct": { "xbrltype": "pureItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "UndrlygSecurityMktPriceChngPct", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Underlying Security Market Price Change, Percent", "terseLabel": "Underlying Security Market Price Change" } } }, "auth_ref": [ "r228" ] }, "blrx_UnregisteredWarrantsIssuedToPurchaseShares": { "xbrltype": "sharesItemType", "nsuri": "http://biolinerx.com/20260630", "localname": "UnregisteredWarrantsIssuedToPurchaseShares", "presentation": [ "http://biolinerx.com/role/EQUITYFINANCINGNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Unregistered Warrants Issued To Purchase Shares", "documentation": "It represents unregistered warrants issued to purchase shares.", "verboseLabel": "Unregistered warrants issued to purchase shares" } } }, "auth_ref": [] }, "ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]", "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year" } } }, "auth_ref": [ "r198" ] }, "blrx_WarrantFourMember": { "xbrltype": "domainItemType", "nsuri": "http://biolinerx.com/20260630", "localname": "WarrantFourMember", "presentation": [ "http://biolinerx.com/role/EQUITYFINANCINGNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Warrant Four [Member]", "documentation": "Warrant Four [Member]", "verboseLabel": "Warrant [Member]" } } }, "auth_ref": [] }, "blrx_WarrantIssuanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://biolinerx.com/20260630", "localname": "WarrantIssuanceCosts", "crdr": "debit", "presentation": [ "http://biolinerx.com/role/CondensedConsolidatedInterimCashFlowStatements" ], "lang": { "en-us": { "role": { "label": "Warrant Issuance Costs", "documentation": "Warrant issuance costs.", "terseLabel": "Warrant issuance costs" } } }, "auth_ref": [] }, "blrx_WarrantOfferingConsideration": { "xbrltype": "monetaryItemType", "nsuri": "http://biolinerx.com/20260630", "localname": "WarrantOfferingConsideration", "crdr": "credit", "presentation": [ "http://biolinerx.com/role/EQUITYFINANCINGNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Warrant Offering Consideration", "documentation": "Tha amount of warrant offering consideration.", "terseLabel": "Warrants offering consideration" } } }, "auth_ref": [] }, "blrx_WarrantSixMember": { "xbrltype": "domainItemType", "nsuri": "http://biolinerx.com/20260630", "localname": "WarrantSixMember", "presentation": [ "http://biolinerx.com/role/EQUITYFINANCINGNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Warrant Six [Member]", "documentation": "Warrant Six [Member]", "terseLabel": "Warrant [Member]" } } }, "auth_ref": [] }, "blrx_Warrants": { "xbrltype": "monetaryItemType", "nsuri": "http://biolinerx.com/20260630", "localname": "Warrants", "crdr": "credit", "calculation": { "http://biolinerx.com/role/CondensedConsolidatedInterimStatementsOfFinancialPosition": { "parentTag": "ifrs-full_CurrentLiabilities", "weight": 1.0, "order": 30.0 } }, "presentation": [ "http://biolinerx.com/role/CondensedConsolidatedInterimStatementsOfFinancialPosition", "http://biolinerx.com/role/FAIRVALUEMEASUREMENTOFWARRANTSUSINGSIGNIFICANTUNOBSERVABLEINPUTSLEVEL3Details" ], "lang": { "en-us": { "role": { "documentation": "The non-current portion of warrants.", "label": "Warrants", "verboseLabel": "Warrants", "periodStartLabel": "Opening Balance", "periodEndLabel": "Closing Balance" } } }, "auth_ref": [] }, "blrx_WarrantsExercised": { "xbrltype": "sharesItemType", "nsuri": "http://biolinerx.com/20260630", "localname": "WarrantsExercised", "presentation": [ "http://biolinerx.com/role/EQUITYFINANCINGNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Warrants Exercised", "documentation": "Number of warrants exercised.", "terseLabel": "Warrants exercised" } } }, "auth_ref": [] }, "blrx_WarrantsExpirationPeriod": { "xbrltype": "stringItemType", "nsuri": "http://biolinerx.com/20260630", "localname": "WarrantsExpirationPeriod", "presentation": [ "http://biolinerx.com/role/EQUITYFINANCINGNarrativeDetails", "http://biolinerx.com/role/SUBSEQUENTEVENTNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Warrants expiration period.", "label": "Warrants expiration period", "verboseLabel": "Warrants expiration period" } } }, "auth_ref": [] }, "blrx_WarrantsIssuedToPurchaseAmericanDepositaryShares": { "xbrltype": "sharesItemType", "nsuri": "http://biolinerx.com/20260630", "localname": "WarrantsIssuedToPurchaseAmericanDepositaryShares", "presentation": [ "http://biolinerx.com/role/SUBSEQUENTEVENTNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Warrants Issued To Purchase American Depositary Shares", "documentation": "It represents warrants issued to purchase American depositary shares.", "verboseLabel": "Warrants issued to purchase ADS" } } }, "auth_ref": [] }, "blrx_WarrantsIssuedToPurchaseShares": { "xbrltype": "sharesItemType", "nsuri": "http://biolinerx.com/20260630", "localname": "WarrantsIssuedToPurchaseShares", "presentation": [ "http://biolinerx.com/role/EQUITYFINANCINGNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Warrants issued to purchase shares.", "label": "Warrants issued to purchase shares", "verboseLabel": "Warrants issued to purchase shares" } } }, "auth_ref": [] }, "ifrs-full_WarrantsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "WarrantsMember", "presentation": [ "http://biolinerx.com/role/CondensedInterimStatementsOfChangesInEquity" ], "lang": { "en-us": { "role": { "label": "Warrants [Member]" } }, "en": { "role": { "documentation": "This member stands for warrants." } } }, "auth_ref": [ "r240" ] }, "blrx_WarrantsReserve": { "xbrltype": "monetaryItemType", "nsuri": "http://biolinerx.com/20260630", "localname": "WarrantsReserve", "crdr": "credit", "calculation": { "http://biolinerx.com/role/CondensedConsolidatedInterimStatementsOfFinancialPosition": { "parentTag": "ifrs-full_EquityAttributableToOwnersOfParent", "weight": 1.0, "order": 20.0 } }, "presentation": [ "http://biolinerx.com/role/CondensedConsolidatedInterimStatementsOfFinancialPosition" ], "lang": { "en-us": { "role": { "documentation": "Represents amount related to warrant.", "label": "Warrants Reserve", "verboseLabel": "Warrants" } } }, "auth_ref": [] }, "blrx_WarrantsTerm": { "xbrltype": "durationItemType", "nsuri": "http://biolinerx.com/20260630", "localname": "WarrantsTerm", "presentation": [ "http://biolinerx.com/role/EQUITYFINANCINGNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Warrants term.", "label": "Warrants Term", "terseLabel": "Warrants term" } } }, "auth_ref": [] }, "ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement2019": { "xbrltype": "perShareItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement2019", "presentation": [ "http://biolinerx.com/role/EQUITYFINANCINGNarrativeDetails", "http://biolinerx.com/role/SUBSEQUENTEVENTNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Weighted average exercise price of other equity instruments exercisable in share-based payment arrangement", "terseLabel": "Exercise price of other equity instruments exercisable" } }, "en": { "role": { "documentation": "The weighted average exercise price of other equity instruments (ie other than share options) exercisable in a share-based payment arrangement. [Refer: Weighted average [member]]" } } }, "auth_ref": [ "r247" ] }, "ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019": { "xbrltype": "perShareItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019", "presentation": [ "http://biolinerx.com/role/SUBSEQUENTEVENTNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Weighted average exercise price of other equity instruments granted in share-based payment arrangement", "verboseLabel": "Exercise price of warrants" } }, "en": { "role": { "documentation": "The weighted average exercise price of other equity instruments (ie other than share options) granted in a share-based payment arrangement. [Refer: Weighted average [member]]" } } }, "auth_ref": [ "r247" ] }, "ifrs-full_WeightedAverageShares": { "xbrltype": "sharesItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "WeightedAverageShares", "presentation": [ "http://biolinerx.com/role/CondensedConsolidatedInterimStatementsOfComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Weighted average number of ordinary shares used in calculating basic earnings per share", "verboseLabel": "WEIGHTED AVERAGE NUMBER OF SHARES USED IN CALCULATION OF BASIC EARNINGS (LOSS) PER ORDINARY SHARE" } }, "en": { "role": { "documentation": "The number of ordinary shares outstanding at the beginning of the period, adjusted by the number of ordinary shares bought back or issued during the period multiplied by a time-weighting factor." } } }, "auth_ref": [ "r10" ] }, "ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]", "terseLabel": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested" } } }, "auth_ref": [ "r196" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "10", "IssueDate": "2025-01-01", "Paragraph": "21", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=10&code=ifrs-tx-2025-en-r&anchor=para_21&doctype=Standard", "URIDate": "2025-03-27" }, "r1": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "16", "IssueDate": "2025-01-01", "Paragraph": "73", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2025-en-r&anchor=para_73_e&doctype=Standard", "URIDate": "2025-03-27" }, "r2": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "142", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2025-en-r&anchor=para_142&doctype=Standard", "URIDate": "2025-03-27" }, "r3": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "2", "IssueDate": "2025-01-01", "Paragraph": "36", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=2&code=ifrs-tx-2025-en-r&anchor=para_36_b&doctype=Standard", "URIDate": "2025-03-27" }, "r4": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "24", "IssueDate": "2025-01-01", "Paragraph": "17", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2025-en-r&anchor=para_17&doctype=Standard", "URIDate": "2025-03-27" }, "r5": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "24", "IssueDate": "2025-01-01", "Paragraph": "19", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2025-en-r&anchor=para_19&doctype=Standard", "URIDate": "2025-03-27" }, "r6": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "27", "IssueDate": "2025-01-01", "Paragraph": "16", "Subparagraph": "b", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2025-en-r&anchor=para_16_b_iii&doctype=Standard", "URIDate": "2025-03-27" }, "r7": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "27", "IssueDate": "2025-01-01", "Paragraph": "17", "Subparagraph": "b", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2025-en-r&anchor=para_17_b_iii&doctype=Standard", "URIDate": "2025-03-27" }, "r8": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "33", "IssueDate": "2025-01-01", "Paragraph": "66", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2025-en-r&anchor=para_66&doctype=Standard", "URIDate": "2025-03-27" }, "r9": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "33", "IssueDate": "2025-01-01", "Paragraph": "67", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2025-en-r&anchor=para_67&doctype=Standard", "URIDate": "2025-03-27" }, "r10": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "33", "IssueDate": "2025-01-01", "Paragraph": "70", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2025-en-r&anchor=para_70_b&doctype=Standard", "URIDate": "2025-03-27" }, "r11": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "36", "IssueDate": "2025-01-01", "Paragraph": "130", "Subparagraph": "f", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2025-en-r&anchor=para_130_f_i&doctype=Standard", "URIDate": "2025-03-27" }, "r12": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "36", "IssueDate": "2025-01-01", "Paragraph": "134", "Subparagraph": "e", "Clause": "iiA", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2025-en-r&anchor=para_134_e_iiA&doctype=Standard", "URIDate": "2025-03-27" }, "r13": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "38", "IssueDate": "2025-01-01", "Paragraph": "118", "Subparagraph": "e", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2025-en-r&anchor=para_118_e_i&doctype=Standard", "URIDate": "2025-03-27" }, "r14": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "38", "IssueDate": "2025-01-01", "Paragraph": "118", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2025-en-r&anchor=para_118_e&doctype=Standard", "URIDate": "2025-03-27" }, "r15": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "38", "IssueDate": "2025-01-01", "Paragraph": "126", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2025-en-r&anchor=para_126&doctype=Standard", "URIDate": "2025-03-27" }, "r16": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "40", "IssueDate": "2025-01-01", "Paragraph": "32A", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=40&code=ifrs-tx-2025-en-r&anchor=para_32A&doctype=Standard", "URIDate": "2025-03-27" }, "r17": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "40", "IssueDate": "2025-01-01", "Paragraph": "76", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=40&code=ifrs-tx-2025-en-r&anchor=para_76&doctype=Standard", "URIDate": "2025-03-27" }, "r18": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "40", "IssueDate": "2025-01-01", "Paragraph": "79", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=40&code=ifrs-tx-2025-en-r&anchor=para_79_d&doctype=Standard", "URIDate": "2025-03-27" }, "r19": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "41", "IssueDate": "2025-01-01", "Paragraph": "50", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=41&code=ifrs-tx-2025-en-r&anchor=para_50&doctype=Standard", "URIDate": "2025-03-27" }, "r20": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "10", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_10&doctype=Standard", "URIDate": "2025-03-27" }, "r21": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "20", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_20&doctype=Standard", "URIDate": "2025-03-27" }, "r22": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "25", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_25&doctype=Standard", "URIDate": "2025-03-27" }, "r23": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "28", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_28&doctype=Standard", "URIDate": "2025-03-27" }, "r24": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "45", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_45&doctype=Standard", "URIDate": "2025-03-27" }, "r25": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "50", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_50_d&doctype=Standard", "URIDate": "2025-03-27" }, "r26": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "24", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2025-en-r&anchor=para_24_a&doctype=Standard", "URIDate": "2025-03-27" }, "r27": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "24", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2025-en-r&anchor=para_24_b&doctype=Standard", "URIDate": "2025-03-27" }, "r28": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "32", "Subparagraph": "a", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2025-en-r&anchor=para_32_a_i&doctype=Standard", "URIDate": "2025-03-27" }, "r29": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "32", "Subparagraph": "a", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2025-en-r&anchor=para_32_a_ii&doctype=Standard", "URIDate": "2025-03-27" }, "r30": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "10", "IssueDate": "2025-01-01", "Paragraph": "22", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=10&code=ifrs-tx-2025-en-r&anchor=para_22&doctype=Standard", "URIDate": "2025-03-27" }, "r31": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "12", "Subparagraph": "f", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_12_f&doctype=Standard", "URIDate": "2025-03-27" }, "r32": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "21", "Subparagraph": "a", "Clause": "iv", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_21_a_iv&doctype=Standard", "URIDate": "2025-03-27" }, "r33": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "21", "Subparagraph": "b", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_21_b_i&doctype=Standard", "URIDate": "2025-03-27" }, "r34": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "B12", "Subparagraph": "b", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B12_b_i&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r35": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "B12", "Subparagraph": "b", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B12_b_ii&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r36": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "B12", "Subparagraph": "b", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B12_b_iii&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r37": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "B12", "Subparagraph": "b", "Clause": "iv", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B12_b_iv&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r38": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "B12", "Subparagraph": "b", "Clause": "ix", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B12_b_ix&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r39": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "B12", "Subparagraph": "b", "Clause": "v", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B12_b_v&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r40": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "B13", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B13_a&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r41": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "13", "IssueDate": "2025-01-01", "Paragraph": "93", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2025-en-r&anchor=para_93_a&doctype=Standard", "URIDate": "2025-03-27" }, "r42": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "13", "IssueDate": "2025-01-01", "Paragraph": "93", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2025-en-r&anchor=para_93_b&doctype=Standard", "URIDate": "2025-03-27" }, "r43": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "13", "IssueDate": "2025-01-01", "Paragraph": "93", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2025-en-r&anchor=para_93_d&doctype=Standard", "URIDate": "2025-03-27" }, "r44": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "13", "IssueDate": "2025-01-01", "Paragraph": "93", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2025-en-r&anchor=para_93_e&doctype=Standard", "URIDate": "2025-03-27" }, "r45": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "13", "IssueDate": "2025-01-01", "Paragraph": "93", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2025-en-r&anchor=para_93&doctype=Standard", "URIDate": "2025-03-27" }, "r46": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "13", "IssueDate": "2025-01-01", "Section": "Disclosure", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2025-en-r&doctype=Standard&dita_xref=IFRS13_g91-99_TI", "URIDate": "2025-03-27" }, "r47": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "15", "IssueDate": "2025-01-01", "Paragraph": "105", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2025-en-r&anchor=para_105&doctype=Standard", "URIDate": "2025-03-27" }, "r48": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "16", "IssueDate": "2025-01-01", "Paragraph": "47", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2025-en-r&anchor=para_47_a&doctype=Standard", "URIDate": "2025-03-27" }, "r49": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "16", "IssueDate": "2025-01-01", "Paragraph": "47", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2025-en-r&anchor=para_47_b&doctype=Standard", "URIDate": "2025-03-27" }, "r50": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "16", "IssueDate": "2025-01-01", "Paragraph": "53", "Subparagraph": "j", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2025-en-r&anchor=para_53_j&doctype=Standard", "URIDate": "2025-03-27" }, "r51": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2025-01-01", "Paragraph": "45", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2025-en-r&anchor=para_45_b&doctype=Standard", "URIDate": "2025-03-27" }, "r52": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2025-01-01", "Paragraph": "45", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2025-en-r&anchor=para_45_d&doctype=Standard", "URIDate": "2025-03-27" }, "r53": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2025-01-01", "Paragraph": "45", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2025-en-r&anchor=para_45&doctype=Standard", "URIDate": "2025-03-27" }, "r54": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2025-01-01", "Paragraph": "47", "Subparagraph": "a", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2025-en-r&anchor=para_47_a_i&doctype=Standard", "URIDate": "2025-03-27" }, "r55": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2025-01-01", "Paragraph": "47", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2025-en-r&anchor=para_47_a&doctype=Standard", "URIDate": "2025-03-27" }, "r56": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2025-01-01", "Paragraph": "47", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2025-en-r&anchor=para_47_b&doctype=Standard", "URIDate": "2025-03-27" }, "r57": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "5", "IssueDate": "2025-01-01", "Paragraph": "33", "Subparagraph": "b", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=5&code=ifrs-tx-2025-en-r&anchor=para_33_b_i&doctype=Standard", "URIDate": "2025-03-27" }, "r58": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "25", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_25&doctype=Standard", "URIDate": "2025-03-27" }, "r59": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "35H", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_35H&doctype=Standard", "URIDate": "2025-03-27" }, "r60": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "35K", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_35K&doctype=Standard", "URIDate": "2025-03-27" }, "r61": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "35M", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_35M&doctype=Standard", "URIDate": "2025-03-27" }, "r62": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "36", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_36&doctype=Standard", "URIDate": "2025-03-27" }, "r63": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2025-01-01", "Paragraph": "23", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_23_a&doctype=Standard", "URIDate": "2025-03-27" }, "r64": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2025-01-01", "Paragraph": "23", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_23&doctype=Standard", "URIDate": "2025-03-27" }, "r65": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2025-01-01", "Paragraph": "28", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_28_a&doctype=Standard", "URIDate": "2025-03-27" }, "r66": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2025-01-01", "Paragraph": "28", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_28_b&doctype=Standard", "URIDate": "2025-03-27" }, "r67": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2025-01-01", "Paragraph": "28", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_28_c&doctype=Standard", "URIDate": "2025-03-27" }, "r68": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2025-01-01", "Paragraph": "28", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_28_d&doctype=Standard", "URIDate": "2025-03-27" }, "r69": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2025-01-01", "Paragraph": "32", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_32&doctype=Standard", "URIDate": "2025-03-27" }, "r70": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2025-01-01", "Paragraph": "33", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_33_a&doctype=Standard", "URIDate": "2025-03-27" }, "r71": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2025-01-01", "Paragraph": "34", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_34&doctype=Standard", "URIDate": "2025-03-27" }, "r72": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "115", "Subparagraph": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_115_i&doctype=Standard", "URIDate": "2025-03-27" }, "r73": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "128", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_128&doctype=Standard", "URIDate": "2025-03-27" }, "r74": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "160", "Subparagraph": "a", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_160_a_i&doctype=Standard", "URIDate": "2025-03-27" }, "r75": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "160", "Subparagraph": "a", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_160_a_ii&doctype=Standard", "URIDate": "2025-03-27" }, "r76": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "160", "Subparagraph": "a", "Clause": "iv", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_160_a_iv&doctype=Standard", "URIDate": "2025-03-27" }, "r77": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "160", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_160_a&doctype=Standard", "URIDate": "2025-03-27" }, "r78": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "160", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_160&doctype=Standard", "URIDate": "2025-03-27" }, "r79": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "164", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_164_b&doctype=Standard", "URIDate": "2025-03-27" }, "r80": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "169", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_169&doctype=Standard", "URIDate": "2025-03-27" }, "r81": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "176", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_176&doctype=Standard", "URIDate": "2025-03-27" }, "r82": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "190", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_190&doctype=Standard", "URIDate": "2025-03-27" }, "r83": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "200", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_200_e&doctype=Standard", "URIDate": "2025-03-27" }, "r84": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "227", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_227&doctype=Standard", "URIDate": "2025-03-27" }, "r85": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "231", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_231&doctype=Standard", "URIDate": "2025-03-27" }, "r86": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "24", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_24_a&doctype=Standard", "URIDate": "2025-03-27" }, "r87": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "24", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_24_b&doctype=Standard", "URIDate": "2025-03-27" }, "r88": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "254", "Subparagraph": "e", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_254_e_ii&doctype=Standard", "URIDate": "2025-03-27" }, "r89": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "263", "Subparagraph": "e", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_263_e_i&doctype=Standard", "URIDate": "2025-03-27" }, "r90": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "263", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_263_e&doctype=Standard", "URIDate": "2025-03-27" }, "r91": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "266", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_266&doctype=Standard", "URIDate": "2025-03-27" }, "r92": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "269", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_269&doctype=Standard", "URIDate": "2025-03-27" }, "r93": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "271", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_271_d&doctype=Standard", "URIDate": "2025-03-27" }, "r94": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "273", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_273&doctype=Standard", "URIDate": "2025-03-27" }, "r95": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "28", "Subparagraph": "a", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_28_a_i&doctype=Standard", "URIDate": "2025-03-27" }, "r96": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "28", "Subparagraph": "a", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_28_a_ii&doctype=Standard", "URIDate": "2025-03-27" }, "r97": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "31", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_31_b&doctype=Standard", "URIDate": "2025-03-27" }, "r98": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "31", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_31&doctype=Standard", "URIDate": "2025-03-27" }, "r99": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "66", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_66&doctype=Standard", "URIDate": "2025-03-27" }, "r100": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "71", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_71&doctype=Standard", "URIDate": "2025-03-27" }, "r101": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "88", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_88_a&doctype=Standard", "URIDate": "2025-03-27" }, "r102": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "95", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_95_a&doctype=Standard", "URIDate": "2025-03-27" }, "r103": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "95", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_95_b&doctype=Standard", "URIDate": "2025-03-27" }, "r104": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "95", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_95&doctype=Standard", "URIDate": "2025-03-27" }, "r105": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "B10", "Subparagraph": "a", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_B10_a_i&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r106": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "B10", "Subparagraph": "a", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_B10_a_ii&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r107": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "B10", "Subparagraph": "a", "Clause": "iv", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_B10_a_iv&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r108": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "B10", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_B10_a&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r109": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "B10", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_B10&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r110": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "B13", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_B13&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r111": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "B9", "Subparagraph": "f", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_B9_f&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r112": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "103", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_103&doctype=Standard", "URIDate": "2025-03-27" }, "r113": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "106", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_106_a&doctype=Standard", "URIDate": "2025-03-27" }, "r114": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "106", "Subparagraph": "d", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_106_d_i&doctype=Standard", "URIDate": "2025-03-27" }, "r115": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "106", "Subparagraph": "d", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_106_d_iii&doctype=Standard", "URIDate": "2025-03-27" }, "r116": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "106", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_106&doctype=Standard", "URIDate": "2025-03-27" }, "r117": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "117", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_117&doctype=Standard", "URIDate": "2025-03-27" }, "r118": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "51", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_51&doctype=Standard", "URIDate": "2025-03-27" }, "r119": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "54", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_54_a&doctype=Standard", "URIDate": "2025-03-27" }, "r120": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "54", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_54_b&doctype=Standard", "URIDate": "2025-03-27" }, "r121": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "54", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_54_c&doctype=Standard", "URIDate": "2025-03-27" }, "r122": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "54", "Subparagraph": "g", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_54_g&doctype=Standard", "URIDate": "2025-03-27" }, "r123": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "54", "Subparagraph": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_54_i&doctype=Standard", "URIDate": "2025-03-27" }, "r124": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "54", "Subparagraph": "q", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_54_q&doctype=Standard", "URIDate": "2025-03-27" }, "r125": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "54", "Subparagraph": "r", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_54_r&doctype=Standard", "URIDate": "2025-03-27" }, "r126": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "55", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_55&doctype=Standard", "URIDate": "2025-03-27" }, "r127": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "66", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_66&doctype=Standard", "URIDate": "2025-03-27" }, "r128": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "69", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_69&doctype=Standard", "URIDate": "2025-03-27" }, "r129": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "78", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_78_e&doctype=Standard", "URIDate": "2025-03-27" }, "r130": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "79", "Subparagraph": "a", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_79_a_i&doctype=Standard", "URIDate": "2025-03-27" }, "r131": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "79", "Subparagraph": "a", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_79_a_ii&doctype=Standard", "URIDate": "2025-03-27" }, "r132": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "79", "Subparagraph": "a", "Clause": "iv", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_79_a_iv&doctype=Standard", "URIDate": "2025-03-27" }, "r133": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "79", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_79_a&doctype=Standard", "URIDate": "2025-03-27" }, "r134": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "79", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_79&doctype=Standard", "URIDate": "2025-03-27" }, "r135": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "81A", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_81A_a&doctype=Standard", "URIDate": "2025-03-27" }, "r136": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "81A", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_81A_c&doctype=Standard", "URIDate": "2025-03-27" }, "r137": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "81B", "Subparagraph": "b", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_81B_b_i&doctype=Standard", "URIDate": "2025-03-27" }, "r138": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "81B", "Subparagraph": "b", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_81B_b_ii&doctype=Standard", "URIDate": "2025-03-27" }, "r139": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "82", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_82_a&doctype=Standard", "URIDate": "2025-03-27" }, "r140": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "82", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_82_b&doctype=Standard", "URIDate": "2025-03-27" }, "r141": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "99", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_99&doctype=Standard", "URIDate": "2025-03-27" }, "r142": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "32", "IssueDate": "2025-01-01", "Paragraph": "IE33", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=32&code=ifrs-tx-2025-en-r&anchor=para_IE33&doctype=Illustrative%20Examples", "URIDate": "2025-03-27" }, "r143": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "16", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_16_b&doctype=Standard", "URIDate": "2025-03-27" }, "r144": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "17", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_17_a&doctype=Standard", "URIDate": "2025-03-27" }, "r145": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "17", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_17_e&doctype=Standard", "URIDate": "2025-03-27" }, "r146": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Section": "A Statement of cash flows for an entity other than a financial institution", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&doctype=Illustrative%20Examples&dita_xref=IAS07_IE_A_TI", "URIDate": "2025-03-27" }, "r147": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "B10", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B10_b&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r148": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "17", "IssueDate": "2025-01-01", "Paragraph": "113", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2025-en-r&anchor=para_113_b&doctype=Standard", "URIDate": "2025-03-27" }, "r149": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "B9", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_B9_b&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r150": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "B9", "Subparagraph": "f", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_B9_f&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r151": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "102", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_102&doctype=Standard", "URIDate": "2025-03-27" }, "r152": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "103", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_103&doctype=Standard", "URIDate": "2025-03-27" }, "r153": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "108", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_108&doctype=Standard", "URIDate": "2025-03-27" }, "r154": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "68", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_68&doctype=Standard", "URIDate": "2025-03-27" }, "r155": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "70", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_70&doctype=Standard", "URIDate": "2025-03-27" }, "r156": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "78", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_78_b&doctype=Standard", "URIDate": "2025-03-27" }, "r157": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "78", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_78_e&doctype=Standard", "URIDate": "2025-03-27" }, "r158": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "IG6", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_IG6&doctype=Implementation%20Guidance", "URIDate": "2025-03-27" }, "r159": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r160": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16", "Subsection": "J", "Paragraph": "a" }, "r161": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1" }, "r162": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i" }, "r163": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r164": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r165": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r166": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r167": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r168": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "ii" }, "r169": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "iii" }, "r170": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "2" }, "r171": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a" }, "r172": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1" }, "r173": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r174": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r175": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r176": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r177": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r178": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "2" }, "r179": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "3" }, "r180": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "b" }, "r181": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a" }, "r182": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1" }, "r183": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r184": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r185": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r186": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r187": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r188": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "2" }, "r189": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "3" }, "r190": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "b" }, "r191": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v" }, "r192": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "1" }, "r193": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "ii" }, "r194": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii" }, "r195": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Subclause": "ii" }, "r196": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "i" }, "r197": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "ii" }, "r198": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "iii" }, "r199": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "iv" }, "r200": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "v" }, "r201": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "vi" }, "r202": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iv" }, "r203": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "vi" }, "r204": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "3" }, "r205": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "4" }, "r206": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "i" }, "r207": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "ii" }, "r208": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iii" }, "r209": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iv" }, "r210": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6" }, "r211": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6", "Subparagraph": "i" }, "r212": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1" }, "r213": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i" }, "r214": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r215": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r216": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r217": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r218": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r219": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "ii" }, "r220": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "iii" }, "r221": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "2" }, "r222": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "1" }, "r223": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2" }, "r224": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "A" }, "r225": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "C" }, "r226": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "D" }, "r227": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "E" }, "r228": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "F" }, "r229": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a" }, "r230": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "1" }, "r231": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "A" }, "r232": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "B" }, "r233": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "C" }, "r234": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "D" }, "r235": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "b", "Paragraph": "1" }, "r236": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Number": "229", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1" }, "r237": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "A", "Number": "229" }, "r238": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Number": "229" }, "r239": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Subclause": "i", "Number": "229" }, "r240": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "33", "IssueDate": "2025-01-01", "Paragraph": "70", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2025-en-r&anchor=para_70_c&doctype=Standard", "URIDate": "2025-03-27" }, "r241": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "16", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_16&doctype=Standard", "URIDate": "2025-03-27" }, "r242": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "17", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_17&doctype=Standard", "URIDate": "2025-03-27" }, "r243": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "20", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_20_a&doctype=Standard", "URIDate": "2025-03-27" }, "r244": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "20", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_20_b&doctype=Standard", "URIDate": "2025-03-27" }, "r245": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "20", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_20&doctype=Standard", "URIDate": "2025-03-27" }, "r246": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "45", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_45&doctype=Standard", "URIDate": "2025-03-27" }, "r247": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IFRS", "Number": "2", "IssueDate": "2025-01-01", "Paragraph": "45", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2025-en-r&anchor=para_45&doctype=Standard", "URIDate": "2025-03-27" }, "r248": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "10", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_10_e&doctype=Standard", "URIDate": "2025-03-27" }, "r249": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "108", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_108&doctype=Standard", "URIDate": "2025-03-27" }, "r250": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "112", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_112_c&doctype=Standard", "URIDate": "2025-03-27" }, "r251": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "55", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_55&doctype=Standard", "URIDate": "2025-03-27" }, "r252": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "78", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_78&doctype=Standard", "URIDate": "2025-03-27" }, "r253": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "85", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_85&doctype=Standard", "URIDate": "2025-03-27" } } }